



92A Systematic Review of Proteomics in Obesity: Unpacking the Molecular Puzzle

Alba Rodriguez-Muñoz^{1,2,3} · Hanieh Motahari-Rad⁴ · Laura Martin-Chaves^{5,6} · Javier Benitez-Porres^{2,7} · Jorge Rodriguez-Capitan^{5,8} · Andrés Gonzalez-Jimenez⁹ · Maria Insenser¹⁰ · Francisco J. Tinahones^{1,2,3,6} · Mora Murri^{1,2,3,4}

Accepted: 14 March 2024
© The Author(s) 2024

Abstract

Purpose of Review The present study aims to review the existing literature to identify pathophysiological proteins in obesity by conducting a systematic review of proteomics studies. Proteomics may reveal the mechanisms of obesity development and clarify the links between obesity and related diseases, improving our comprehension of obesity and its clinical implications.

Recent Findings Most of the molecular events implicated in obesity development remain incomplete. Proteomics stands as a powerful tool for elucidating the intricate interactions among proteins in the context of obesity. This methodology has the potential to identify proteins involved in pathological processes and to evaluate changes in protein abundance during obesity development, contributing to the identification of early disease predisposition, monitoring the effectiveness of interventions and improving disease management overall. Despite many non-targeted proteomic studies exploring obesity, a comprehensive and up-to-date systematic review of the molecular events implicated in obesity development is lacking. The lack of such a review presents a significant challenge for researchers trying to interpret the existing literature.

Summary This systematic review was conducted following the PRISMA guidelines and included sixteen human proteomic studies, each of which delineated proteins exhibiting significant alterations in obesity. A total of 41 proteins were reported to be altered in obesity by at least two or more studies. These proteins were involved in metabolic pathways, oxidative stress responses, inflammatory processes, protein folding, coagulation, as well as structure/cytoskeleton. Many of the identified proteomic biomarkers of obesity have also been reported to be dysregulated in obesity-related disease. Among them, seven proteins, which belong to metabolic pathways (aldehyde dehydrogenase and apolipoprotein A1), the chaperone family (albumin, heat shock protein beta 1, protein disulfide-isomerase A3) and oxidative stress and inflammation proteins (catalase and complement C3), could potentially serve as biomarkers for the progression of obesity and the development of comorbidities, contributing to personalized medicine in the field of obesity. Our systematic review in proteomics represents a substantial step forward in unravelling the complexities of protein alterations associated with obesity. It provides valuable insights into the pathophysiological mechanisms underlying obesity, thereby opening avenues for the discovery of potential biomarkers and the development of personalized medicine in obesity

Keywords Obesity · Proteomics · Metabolism · Personalized medicine

Introduction

Obesity is defined as a nutritional, endocrine and metabolic disorder characterized by an abnormal accumulation of body fat and subclinical chronic inflammation. More than 1 billion people are grappling with obesity [1], which is associated

with an increased risk of morbidity and mortality, causing 5 million deaths every year along with overweight [2] <https://www.who.int>. It is also linked to several chronic diseases such as type 2 diabetes (T2DM), metabolic syndrome, liver disease or cardiovascular diseases and some types of cancer [2].

Body mass index (BMI) is the main parameter used to classify obesity; however, this index does not allow to evaluate body composition because it does not differentiate muscle mass from adipose tissue (AT) or bone [3]. Consequently, it is easy to overestimate obesity and predict

Francisco J. Tinahones and Mora Murri both share last authorship.

Extended author information available on the last page of the article

wrongly health outcomes. On the one hand, a proportion of individuals with obesity seems to be protected against worsening of metabolic health, whereas at the other end of the spectrum, there are normal weight individuals who have the metabolic abnormalities usually associated with obesity [4]. This paradox hampers new diagnosis and treatment approaches of obesity and all its comorbidities. Additionally, when considering obesity, every person should be assessed based on their own specific and unique circumstances [5]. Therefore, it is essential to find novel molecular parameters that provide a broader understanding of the molecular events that control body weight.

As mentioned earlier, the quality and quantity of body fat accumulation may be responsible for a major risk of developing several pathologies. This is possible due to the fact that adipose tissue (AT) has secretory functions and acts as a metabolic and endocrine organ, capable of producing metabolic regulators [6]. Secreted proteins as well as plasma or serum proteome represent an important group of molecules that provide us valuable insights for monitoring physiological changes caused by obesity [7]. Obesity can alter or even change some proteins in different tissues; an unhealthy amount of body fat caused by protein interactions and modifications are responsible for different affections related to the accumulation of AT. For example, the accumulation of AT around the throat and larynx causes sleep apnoea [8], whereas its accumulation around the heart can lead atrial fibrillation and heart failure [9]. Additionally, obesity can also increase the secretion of certain hormones and pro-inflammatory mechanisms which may produce infertility due to an increase in male hormones, among other issues [10]. The accumulation of fat around various tissues has the potential to induce alterations and modifications at the protein level, as well as in protein–protein interactions.

Proteomics—a powerful approach part of the “OMICS” spectrum—is a promising tool to elucidate the intricate interplay between proteins and obesity. Proteomics can identify and measure changes in protein levels and profiles in response to genetic variations, pathological conditions or physiological states [11]. This technology allows us to investigate how obesity affects cells in different body fluids and tissues such as, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle (SKM), liver, ovarian granulosa cells (GCs), platelets, plasma, sperm, endometrial tissue or extracellular vesicles (EVs).

Obesity, being a multifaceted condition influenced by genetic, environmental, and lifestyle factors, presents a complex disease model. Despite many non-targeted proteomic studies exploring obesity, a comprehensive and up-to-date systematic review of the molecular events implicated in obesity development is lacking. The lack of such a review presents a significant challenge for researchers trying to interpret the existing literature.

Our goal, as the first systematic review of non-targeted proteomics in obesity, is to evaluate all available studies to identify pathophysiological mechanisms that may improve our comprehension of obesity and its clinical implications. We aim to determine which proteins or processes should be prioritized over others while selecting potential targets for hypothesis-driven research. In our review, we have included the latest published research comparing different proteomics profiles of patients with obesity and normoweight subjects. This review provides valuable insights that may contribute to the identification of novel therapeutic targets, and to facilitate the development of new treatments for obesity.

Methods

Registration and Protocol

This systematic review was registered a priori at PROSPERO (human studies: CRD42023212429) and structured following the PRISMA guidelines [12].

Study Design

We conducted a systematic review of original studies reporting proteomics analysis in general adult human population up to February of 2023. Proteomics analyses were defined as high-throughput analyses conducted at the protein level, aiming to uncover novel insights through non-targeted approaches [13]. Five different electronic databases were searched: PubMed, EMBASE, Scopus, Web of Science (WOS), and Directory of Open Access Journals (DOAJ). Body mass index (BMI) was used to stratify participants as patients with obesity ($\text{BMI} > 30 \text{ kg/m}^2$) or normoweight controls ($18.5 \text{ kg/m}^2 > \text{BMI} < 25 \text{ kg/m}^2$).

Search Strategy and Data Collection

All the publications that studied the association between proteins with obesity were searched and reviewed. We included studies published using non-targeted proteomics approaches and identifying a characteristic pattern of proteins in patients with obesity compared to healthy normoweight matching controls. In addition, a hand search of the references of the retrieved articles and relevant reviews was performed to identify other potentially eligible studies.

The search algorithm was: “Obesity” [Title] AND “Proteomic” [Title] OR “Proteomics” and the published language was limited to English. We only included studies in humans. Language was limited to English. Experimental methods, protocols, reviews or systematic reviews, abstracts and conference proceedings were excluded from this research. At least two emails with logical intervals (about 3 weeks) were

sent to the corresponding author of the manuscript to eliminate the limitations of no access to full text.

All studies were independently screened by three research. Data were extracted independently from included studies by two authors (AR, MI). Disagreements were resolved by discussion between the two authors and consultation was made with a third author (MM). We classified every selected study according to characteristics of the cohort: age, BMI, matching criteria, as it is showed in Table 1. Moreover, analytical, identification or software method used in selected manuscripts, as well as biomarker source and the different abundance of expressed proteins are represented in Table 2.

Quality Assessment

The quality assessment of the included studies was assessed independently from included studies by two authors (AR, MI). Disagreements were resolved by discussion between the two authors, and consultation was made with a third author (MM). Study quality was appraised using the Critical Appraisal Skills Programme (CASP) checklists (Online resource 1) in all the included studies of the present systematic review.

Results

Characteristics of the Studies

PRISMA diagram of the individual proteomics systematic search is summarised in Fig. 1. Then, 3934 manuscripts were identified and, according to inclusion criteria, 16 studies were included in systematic review. All articles extracted from mentioned databases were precisely evaluated based on the full text and reported supplementary data.

A summary of the characteristics of the eligible studies for systematic review are summarized in Table 1. The total number of participants included in the current systematic review was 149 normoweight subjects and 152 patients with obesity. The mean age of participants ranged from 24 [14] to 52 years [15]. In 7 studies, control and obese groups were matched by age and gender, 6 studies by age and 3 studies by gender. Different non-targeted proteomics approaches were addressed in order to compare proteins from patients with obesity and lean subject. Examined samples expressing different protein abundance included extracellular vesicles (EVs), platelets, SAT, VAT, SKM, endometrial tissue, GCs and sperm. Analytical and identification methods of the included studies are represented in Table 2. Analytical method included two-dimensional

Table 1 Characteristics of published studies included in systematic review comparing samples from patients with obesity and normoweight subjects

Author (year)	Country	Simple size (n)		Age (years)		BMI (kg/m ²)		Matching criteria
		Normoweight	Obesity	Normoweight	Obesity	Normoweight	Obesity	
Barrachina et al. 2018	Spain	22	22	35 ± 11	35 ± 11	22 ± 2	46 ± 5	Age and gender
Barrachina et al. 2019	Spain	10	10	34 ± 11	34 ± 12	22 ± 2	46 ± 6	Age and gender
Benabdelkamel et al. 2015	Saudi Arabia	7	7	36 ± 5	38 ± 7	23 ± 0	45 ± 4	Age
Boden et al. 2008	USA	6	6	36 ± 4	44 ± 4	24 ± 1	34 ± 2	Age
Giebelstein et al. 2012	Germany	10	11	51 ± 1	49 ± 1	24 ± 1	34 ± 1	Age
Giuliani et al. 2022	USA	6	6	26 ± 9	31 ± 6	22 ± 3	38 ± 6	Age and gender
Grande et al. 2019	Italy	4	4	43 ± 4	44 ± 5	22 ± 1	50 ± 1	Age and gender
Hittel et al. 2005	USA	6	6	45 ± 3	38 ± 3	24 ± 1	54 ± 4	Gender
Hwang et al. 2010	USA	8	8	37 ± 4	44 ± 3	24 ± 1	32 ± 1	Age and gender
Karlsson et al. 2009	Sweeden	9	10	47 ± 16	52 ± 19	21 ± 3	33 ± 3	Age and gender
Kras et al. 2018	USA	16	17	33 ± 3	32 ± 3	23 ± 1	34 ± 1	Age and gender
Kriegel et al. 2009	Germany	5	2	24 ± 4	38 ± 22	22 ± 2	33 ± 3	Gender
Oberbach et al. 2011	Germany	15	15	24 ± 2	24 ± 3	24 ± 2	37 ± 7	Age
Pini et al. 2020	USA	5	5	38 ± 2	41 ± 2	24 ± 0	33 ± 1	Age
Shang et al. 2019	China	8	9	44 ± 7	34 ± 10	22 ± 1	49 ± 10	Gender
Si et al. 2021	China	12	14	31 ± 2	38 ± 1	21 ± 0	31 ± 1	Age

Results are shown as mean ± standard deviation (mean ± SD)

Table 2 Summary of published studies comparing samples from patients with obesity and normoweight subjects using proteomic approaches

Author (year)	Analytical Method	Identification Method	Analysis software	Sample	Protein abundance
Barrachina et al. 2018	2D-DIGE	LC-MS/MS or MALDI-TOF MS	Progenesis SameSpots v 4,5	EVs	22 (9 ↓, 13 ↑)
Barrachina et al. 2019	2D-DIGE	LC-MS/MS or MALDI-TOF/TOF	Progenesis SameSpots v 4,5	Platelets	32 (19 ↓, 13 ↑)
Benabdelkamel et al. 2015	2D-DIGE	MALDI-TOF MS	Progenesis SameSpots v 3.3	SAT	61 (30 ↓, 31 ↑)
Boden et al. 2008	2D-PAGE	MALDI-TOF/TOF	PDQuest	SAT	20 (7 ↓, 13 ↑)
Giebelstein et al. 2012	2D-DIGE	nanoHPLC/ESI-MS/MS	DeCyder-2D-V6.5	SKM	26 (12 ↓, 14 ↑)
Giuliani et al. 2022	Bis-Tris NuPAGE	nano LC-MS/MS	R package DEP	Endometrial tissue	16 (14 ↓, 2 ↑)
Grande et al. 2019	Label free	LC-MS/MS	MaxQuant (MQ) v.1.5.0.30	Platelets	46 (3 ↓, 43 ↑)
Hittel et al. 2005	2D-PAGE	MALDI-TOF/TOF MS/MS	Z3 software	SKM	13 (4 ↓, 9 ↑)
Hwang et al. 2010	Label free	1D-HPLC-ESI-MS/MS	Affymetrix software	SKM	15 (6 ↓, 9 ↑)
Karlsson et al. 2009	2D-PAGE	MALDI-TOF MS	PDQuest	Plasma	11 (6 ↓, 5 ↑)
Kras et al. 2018	HPLC-ESI-MS-MS	HPLC-ESI-MS-MS	Proteome software v.4.6.1	SKM	70 (43 ↓, 27 ↑)
Kriegel et al. 2009	2D-DIGE	MALDI-TOF/TOF MS/MS	DeCyder software 5.0	Sperm	9 (6 ↓, 3 ↑)
Oberbach et al. 2011	2D-DIGE	MALDI-MS/MS Nano-LC-ESI_MS/MS	Delta2D v3.6	Plasma	6 (6 ↑)
Pini et al. 2020	Label free	LC-MS	Proteome software v.4.8.9	Sperm	26 (23 ↓, 3 ↑)
Shang et al. 2019	Label free	1D-LC-MS/MS	Progenesis software v 4.0	VAT	30 (10 ↓, 20 ↑)
Si et al. 2021	TMT	LC/MS	Limma package R 4.1.0	GCs	10 (10↑)

Analytical and identification method of proteins of studies included in systematic review as well as analysis software employed for proteomics analysis is shown. Every expressed protein found showing different abundance are represented in last column as "↑", increased and "↓", decreased

2D-DIGE two-dimensional difference gel electrophoresis, *2D-PAGE* two-dimensional polyacrylamide gel electrophoresis, *Bis-Tris NuPAGE* protein gel electrophoresis, *HPLC-ESI-MS-MS* high performance liquid chromatography-electrospray tandem mass spectrometry, *TMT* tandem mass Tag, *LC-MS/MS* liquid chromatography mass spectrometry, *MALDI-TOF MS* matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry, *Nano-LC-ESI_MS/MS* nano-high performance liquid chromatography/electrospray ionisation mass spectrometry, *1D-HPLC-ESI-MS/MS* 1D high performance-liquid chromatography-mass spectrometry, *MALDI-MS/MS* matrix-assisted laser desorption/ionisation mass spectrometry, *Nano-LC-ESI_MS/MS* nano liquid chromatography tandem mass spectrometry, *1D-LC-MS/MS* 1D-liquid chromatography-mass spectrometry, *EVs* extracellular vesicles, *SAT* subcutaneous adipose tissue, *VAT* visceral adipose tissue, *GCs* ovarian granulosa cells, *SKM* skeletal muscle

difference gel electrophoresis (2D-DIGE), two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), protein gel electrophoresis NuPAGE Bis-Tris, high performance liquid chromatography-electrospray tandem mass spectrometry (HPLC-ESI-MS-MS), tandem mass tag (TMT) and label free. Identification methods included liquid chromatography mass spectrometry (LC-MS/MS), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), nano-high performance liquid chromatography/electrospray ionisation mass spectrometry (Nano-LC-ESI_MS/MS), 1D-high performance-liquid chromatography-mass spectrometry (1D-HPLC-ESI-MS/MS), matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS/MS), nano liquid chromatography tandem mass spectrometry (Nano-LC-ESI_MS/MS) and 1D-liquid

chromatography-mass spectrometry (1D-LC-MS/MS). Full name of identified proteins along with the corresponding genes can be found in Table 3. UniProt Software was employed to provide comprehensive and functional information of these proteins. Molecular functions, type of analyse sample and protein abundance were reported according to each study.

A Proteomics Approach to Obesity

All outcome data were semi-quantitative, i.e. relative protein abundance. In total, the abundance of 362 proteins was reported to be statistically different between individuals with obesity compared to normoweight controls.




Fig. 1 Flow chart for study identification and selection

Forty-one proteins were found to be altered in at least 2 studies (Table 3) and were described in detail according to their function in this section. As those proteins were not reported in the same kind of samples in at least 3 different studies, a meta-analysis was not performed.

Proteins Related to Metabolic Pathways

Obesity involves a sustained abundance of available energy; therefore, metabolic pathways that play an important role in maintaining cellular energy homeostasis are often dysregulated under this condition [16]. The excess of energy intake associated with the progression of obesity can result in hyperglycaemia, hyperinsulinemia and an increase in fat mass. Moreover, the expansion of AT requires the formation of new blood vessels that supply nutrients and oxygen to proliferate adipocyte cells. Multiple proteins orchestrate the processes required for the efficient production of this energy demand [17]. In this regard, 7 proteins related to metabolic pathways have shown a consistent decrease in subjects with obesity as compared to their normal-weight counterparts,

while 3 proteins were found to be increased and 3 proteins were found increased/decreased in different studies.

Alcohol Dehydrogenase Class-3 Alcohol dehydrogenase class-3 (ADH5) possesses a great ability to metabolize long-chain alcohols, playing a significant role in the metabolism of formaldehyde in the human body. They have attracted considerable interest due to its detoxifying role, modulating the effects of ingested ethanol, tissue damage and developmental abnormalities [18]. A previous study in obesity has shown that ADH5 transcript is significantly increased in brown adipose tissue (BAT) from patients with obesity, suggesting its role in protecting BAT against obesity-associated metabolic dysfunction [19]. Moreover, differential expression of ADH5 abundance during gestation and lactation has been correlated with weight gain in early life [20]. Decreased abundance of ADH5 together with some other proteins in obesity compared to normoweight patients was related to several biological processes, including oxidative stress, inflammation, translation, DNA damage repair and sperm function, being significantly less abundant in the sperm of

Table 3 Characteristics of proteins found in more than two samples of patients with obesity compared to normoweight subjects in original studies included in the systematic review

Protein	Uniprot number	Gen	Molecular function	Sample	Dysregulated proteins	Study
Actin	P60709	ACTB	*Polymerizes to produce filaments that form cross-linked networks in the cytoplasm of cells *Cell motility and contraction. Regulate gene transcription and motility and repair of damaged DNA	Platelets	↑	Barrachina et al. 2019
				SKM	↓	Hittle et al. 2005
				Platelets	↓	Grande et al. 2019
Albumin	P02768	ALB	*Regulation of the colloidal osmotic pressure of blood *Binds water, Ca ²⁺ , Na ⁺ , K ⁺ , fatty acids, hormones, bilirubin, and drugs. *Major calcium, magnesium & zinc transporter in plasma	Platelets	↑	Barrachina et al. 2019
				SKM	↑	Hittle et al. 2005
				SAT	↑	Benabdelkamel et al. 2015
Alcohol dehydrogenase class-3	P11766	ADH5	*Catalyzes the oxidation of long-chain primary alcohols and the oxidation of S-(hydroxymethyl) glutathione * Also oxidises long chain omega-hydroxy fatty acids, such as 20-HETE, producing both the intermediate aldehyde, 20-oxoarachidonate and the product, a dicarboxylic acid	Sperm	↓	Pini et al. 2020
				Platelets	↓	Grande et al. 2019
Aldehyde dehydrogenase	P05091	ALDH2	*Catalytic activity: Required for clearance of cellular formaldehyde, a cytotoxic and carcinogenic metabolite that induces DNA damage	SAT	↑	Boden et al. 2008
				SAT	↓	Benabdelkamel et al. 2015
				SKM	↓	Kras et al. 2018
Alpha enolase	P06733	ENO1	*Glycolytic enzyme the catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate *Involved in various processes such as growth control, hypoxia tolerance and allergic responses *Stimulates immunoglobulin production	SAT	↓	Benabdelkamel et al. 2015
				SAT	↓	Boden et al. 2008

Table 3 (continued)

Protein	Uniprot number	Gen	Molecular function	Sample	Dysregulated proteins	Study
Amyloid P-component, serum	P02743	APCS	*Interacts with DNA and histones and may scavenge nuclear material released from damaged circulating cells *May also function as a calcium-dependent lectin	EVs Plasma	↑ ↑	Barrachina et al. 2018 Oberbach et al. 2011
Annexin A5	P08758	ANXA5	*Anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade	Platelets SAT	↑ ↑	Barrachina et al. 2019 Benabdelkamel et al. 2015
Apolipoprotein A-I	P02647	APOA1	*Participates in the reverse transport of cholesterol from tissues to the liver for excretion *Activates spermatozoa motility	SAT Plasma	↓ ↓	Benabdelkamel et al. 2015 Karlsson et al. 2009
Apolipoprotein B-100	P04114	APOB	*It is a major protein constituent of LDL and VLDL *It functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor	VAT Plasma	↑ ↑	Shang et al. 2019 Karlsson et al. 2009
ATP synthase subunit beta	P06576	ATP5F1B	*Produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain	SAT SAT	↑ ↑	Benabdelkamel et al. 2015 Boden et al. 2008

Table 3 (continued)

Protein	Uniprot number	Gen	Molecular function	Sample	Dysregulated proteins	Study
Catalase	P04040	CAT	*Catalyzes the degradation of hydrogen peroxide (H ₂ O ₂) to water and oxygen, thereby protecting cells from the toxic effects of hydrogen peroxid *Promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells and normal and transformed fibroblast cells	SAT	↓	Benabdelkamel et al. 2015
				SKM	↓	Kras et al. 2018
Coagulation factor V	P12259	F5	*Central regulator of haemostasis. It serves as a critical cofactor for the prothrombinase activity of factor Xa that results in the activation of prothrombin to thrombin	EVs	↓	Barrachina et al. 2018
				Platelets	↑	Grande et al. 2019
Complement C3	P01024	C3	*C3 plays a central role in the activation of the complement system *Acts as a chemoattractant for neutrophils	EVs	↑	Barrachina et al. 2018
				Plasma	↑	Oberbach et al. 2011
Creatine Kinase B- type	P12277	CKB	*Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens *It plays a central role in energy transduction in tissues with large, fluctuating energy demands *Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle	SAT	↓	Benabdelkamel et al. 2015
				VAT	↓	Shang et al. 2019

Table 3 (continued)

Protein	Uniprot number	Gen	Molecular function	Sample	Dysregulated proteins	Study
Crystallin B chain, alpha	P02511	CRYAB	*May contribute to the transparency and refractive index of the lens. Has chaperone-like activity, preventing aggregation of various proteins under a wide range of stress conditions. In lens epithelial cells, stabilizes the ATP6V1A protein, preventing its degradation by the proteasome (By similarity)	SAT SAT	↑ ↑	Benabdelkamel et al. 2015 Boden et al. 2008
D-lactate dehydrogenase, mitochondrial	Q86WU2	LDHD	*Involved in D-lactate catabolic process	VAT	↓	Shang et al. 2019
Desmin	P17661	DES	*Essential for proper muscular structure and function *Plays a crucial role in maintaining the structure of sarcomeres, inter-connecting the Z-disks and forming the myofibrils	SKM SKM SKM	↓ ↓ ↑	Kras et al. 2018 Hwang et al. 2010 Giebelstein et al. 2012
Dihydrolipoyllysine residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial	P36957	DLST	*Component of the 2-oxoglutarate dehydrogenase complex that catalyzes the overall conversion of 2-oxoglutarate to succinyl-CoA and CO2Catalytic activity	Platelets SKM SAT	↑ ↓ ↓	Barrachina et al. 2019 Kras et al. 2018 Boden et al. 2008
Endoplasmic reticulum chaperone BiP	P11021	HSPA5	*Endoplasmic reticulum chaperone that plays a key role in protein folding and quality control in the endoplasmic reticulum lumen *Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10/ERdj5	SAT Platelets	↑ ↓	Benabdelkamel et al. 2015 Grande et al. 2019

Table 3 (continued)

Protein	Uniprot number	Gen	Molecular function	Sample	Dysregulated proteins	Study
Fibrinogen beta chain	P02675	FGB	*Mayor function in haemostasis as one of the primary components of blood clots	EVs	↑	Barrachina et al. 2018
			*Stabilize the lesion and guide cell migration during re-epithelialization during the early stages of wound repair	Platelets	↑	Barrachina et al. 2019
Fibrinogen gamma chain	P02679	FGG	*Mayor function in haemostasis as one of the primary components of blood clots	EVs	↑	Barrachina et al. 2018
			*Stabilize the lesion and guide cell migration during re-epithelialization during the early stages of wound repair	SKM	↑	Giebelstein et al. 2012
Galectin-1	P09382	LGALS1	*Lectin that binds beta-galactoside and a wide array of complex carbohydrates	SAT	↑	Boden et al. 2008
			*Plays a role in regulating apoptosis, cell proliferation and cell differentiation	SAT	↑	Benabdelkamel et al. 2015
Gamma-synuclein	O76070	SNCG	*Inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase			
			*Strong inducer of T-cell apoptosis			
			*Plays a role in neurofilament network integrity. May be involved in modulating axonal architecture during development and in the adult	SAT VAT	↑ ↑	Boden et al. 2008 Shang et al. 2019

Table 3 (continued)

Protein	Uniprot number	Gen	Molecular function	Sample	Dysregulated proteins	Study
Glutathione-S-transferase P	P09211	GSTP1	*Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGI2) *Participates in the formation of novel hepxilin regioisomers *Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration	SAT	↑	Boden et al. 2008
				Platelets	↓	Grande et al. 2019
Glycerinaldehyde-3-phosphate dehydrogenase	P0440	GAPDH	*Key enzyme in glycolysis that catalyzes the first step of the pathway by converting D-glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-glyceroyl phosphate *Modulates the organization and assembly of the cytoskeleton	SKM	↑	Hittle et al. 2005
				SKM	↑	Griebelstein et al. 2012
Heat shock protein beta-1	P0479	HSPB1	*Small heat shock protein which functions as a molecular chaperone probably maintaining denatured proteins in a folding-competent state *Through its molecular chaperone activity may regulate numerous biological processes including the phosphorylation and the axonal transport of neurofilament proteins *Plays a role in stress resistance and actin organization	Platelets	↓	Barrachina et al. 2019
				SAT	↑	Boden et al. 2008
				SAT	↓	Benabdelkamel et al. 2015

Table 3 (continued)

Protein	Uniprot number	Gen	Molecular function	Sample	Dysregulated proteins	Study
Heat shock protein beta-6	O14558	HSPB6	*Plays a role in regulating muscle function such as smooth muscle vasorelaxation and cardiac myocyte contractility *May regulate myocardial angiogenesis implicating KDR *Small heat shock protein which functions as a molecular chaperone probably maintaining denatured proteins in a folding-competent state *Plays a role in regulating muscle function such as smooth muscle vasorelaxation and cardiac myocyte contractility	SAT SAT	↑ ↑	Boden et al. 2008 Benabdelkamel et al. 2015
Haemoglobin subunit alpha	P6990	HBA1	*Involved in oxygen transport from the lung to the various peripheral tissues	EVs SAT SKM SKM EVs SAT	↓ ↑ ↑ ↑ ↓ ↑	Barrachina et al. 2018 Benabdelkamel et al. 2015 Hittle et al. 2005 Giebelstein et al. 2012 Barrachina et al. 2018 Benabdelkamel et al. 2015
Haemoglobin subunit beta	P68871	HBB	*Involved in oxygen transport from the lung to the various peripheral tissues	EVs	↓	Barrachina et al. 2018
IgGfc-binding protein	Q9Y6R7	FCGBP	*May be involved in maintenance of the mucosal structure as a gel-like component of the mucosa	EVs Endometrial tissue	↓ ↑	Barrachina et al. 2018 Giuliani et al. 2022
Integrin alpha-IIb	P08514	ITGA2B	*Receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. *Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen	Platelets Platelets	↑ ↓	Barrachina et al. 2019 Grande et al. 2019

Table 3 (continued)

Protein	Uniprot number	Gen	Molecular function	Sample	Dysregulated proteins	Study
Lysozyme C	P61626	LYZ	*Bacteriolytic function/ catalytic activity; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunogens *It is capable of both hydrolysis and transglycosylation; it also shows a slight esterase activity. It acts rapidly on both peptide-substituted and unsubstituted peptidoglycan, and slowly on chitin oligosaccharides	Platelets VAT Plasma	↓ ↑ ↓	Barrachina et al. 2019 Shang et al. 2019 Karlsson et al. 2009
Malate dehydrogenase, cytoplasmic	P11708	MDH1	*Catalyzes the reduction of aromatic alpha-keto acids in the presence of NADH. Plays essential roles in the malate-aspartate shuttle and the tricarboxylic acid cycle, important in mitochondrial NADH supply for oxidative phosphorylation *Mediates the uptake of pyruvate into mitochondria	Platelets SKM	↓ ↓	Grande et al. 2019 Giebelstein et al. 2012
Mitochondrial pyruvate carrier-1	Q9Y5U8	MPC1		SKM	↓	Kras et al. 2018
Myosin light-chain polypeptide-6	P60660	MYL6	*Regulatory light chain of myosin. Does not bind calcium	Sperm SAT Platelets	↓ ↑ ↓	Pini et al. 2020 Boden et al. 2008 Grande et al. 2019
Parkinson disease protein-7	Q99497	PARK7	*Multifunctional protein with controversial molecular function which plays an important role in cell protection against oxidative stress and cell death acting as oxidative stress sensor and redox-sensitive chaperone and protease *Catalyzes the formation, isomerization, and reduction or oxidation of disulfide bonds	SAT SKM	↑ ↑	Benabdelkamel et al. 2015 Kras et al. 2018
Protein disulfide-isomerase A3	P30101	PDIA3		SAT Platelets	↓ ↓	Boden et al. 2008 Grande et al. 2019

Table 3 (continued)

Protein	Uniprot number	Gen	Molecular function	Sample	Dysregulated proteins	Study
Phosphatidylinositol 5 phosphate 4 kinase type 2 alpha	P48426	PIP4K2A	*Catalyzes the phosphorylation of phosphatidylinositol 5-phosphate (PtdIns5P) on the fourth hydroxyl of the myo-inositol ring, to form phosphatidylinositol 4,5-bis-phosphate. Has both ATP- and GTP-dependent kinase activities	Platelets	↓	Barrachina et al. 2019
				Platelets	↓	Grande et al. 2019
Pyruvate kinase	P30613	PKM	*Catalyzes the final rate-limiting step of glycolysis by mediating the transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating ATP	SKM	↑	Kras et al. 2018
				SKM	↓	Hittle et al. 2005
				Platelets	↓	Grande et al. 2019
Troponyosin alpha-1 chain	P09493	TPM1	*Binds to actin filaments in muscle and non-muscle cells. Plays a central role, in association with the troponin complex, in the calcium dependent regulation of vertebrate striated muscle contraction	Platelets	↑	Barrachina et al. 2019
				Platelets	↓	Grande et al. 2019
Vimentin	P08670	VIM	*Class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells *Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally	SAT	↑	Boden et al. 2008

men with obesity compared with healthy weight controls [21]. Low protein abundance of ADH5, thus, suggest that oxidative stress together with other biological process as inflammation are closely tied to reproductive dysfunction in men with obesity, compromising their fertility [21]. Additionally, patients with obesity have reduced abundance of ADH5 in platelets [22].

Aldehyde Dehydrogenase Aldehyde dehydrogenase (ALDH2) is an important enzyme that eliminates toxic aldehydes by catalysing their oxidation to non-reactive acids. There is a consistent association with ALDH2 and obesity-related features including BMI, waist circumference, waist-to-hip ratio, and visceral fat accumulation [23]. Boden et al. revealed an increase of ALDH2 on SAT of patients with obesity and IR [24]. Those results differ from Benabdelkamel et al. who reported a decrease in abundance of this antioxidant enzyme on SAT [25]. Low abundance of ALDH2 is known to lead accumulation of toxic acetaldehyde and lipid aldehydes as well as to decrease in lipolysis within the mature adipocytes of SAT; however, these reported differences could be explained by the difference of proteomics analysis employed, more recent in the case of Benabdelkamel et al. [25] and the significant differences in BMI of population with obesity from both studies [24, 25]. Boden et al. employed subcutaneous fat biopsies from the upper thighs of six nondiabetic subjects with obesity while Benabdelkamel et al. employed SAT obtained by liposuction from patients with morbid obesity [24, 25]. On the other side, a decreased ALDH2 abundance was also found in mitochondria isolated from SKM of individuals with obesity compared to lean healthy controls [26], highlighting how obesity can alter the expression of mitochondrial proteins regulating key metabolic processes in SKM, including ATP production or fatty acid oxidation [27, 28].

Alpha-Enolase Alpha-enolase (ENO1) is a glycolytic enzyme involved in various processes such as energy or free fatty acid metabolism, growth control, and hypoxia tolerance [29]. Previous studies in obesity have reported decreased levels of ENO1 in adults with obesity and T2DM. It proves that inhibiting the non-glycolytic functions of alpha-enolase can generate an antidiabetic effect and weight loss in those individuals; however, it is needed further research [29]. In this regard, ENO1 downregulation have been associated with weight regain in patients with obesity who followed a weight loss program, indicating the role of ENO1 expression changes on finding target for preventing weight regain and treat metabolic disorders [30]. These findings are consistent with decreased levels of ENO1 abundance found on SAT of patients with obesity in two of the original manuscripts included in the present systematic review. A significant decrease in the abundance of this enzyme was also reported

by Benabdelkamel et al., highlighting alterations in energy metabolism, including a decrease in the glycolytic activity due to weight gain in obesity [25].

Apolipoprotein A-I Apolipoprotein A-I (APOA1) is the major peptide of human plasma high-density lipoproteins (HDL), which are crucial for reverse cholesterol transport from tissues to the liver excretion. This apolipoprotein has anti-inflammatory, antiatherogenic and anti-thrombotic properties, interacting with HDL particles and giving them their cardioprotective characteristics. Moreover, previously, it has been reported that plasma levels of APOA1 are inversely associated with some metabolic conditions, including T2DM, hyperlipidaemia, NAFLD and obesity [31]. Some other reported lipoprotein abnormalities, including decreased levels of APOA1 in patients with obesity compared to lean individuals [32]. In this regard, APOA1 abundance was found to be decreased in plasma from patients with obesity compared to healthy control individuals [15]. Those new findings are consistent with Benabdelkamel et al. who found significantly decreased APOA1 abundance on SAT of patients with morbid obesity compared to participants with overweight or lean controls [25]. Moreover, LDL proteome of women with obesity showed higher levels of APOA1 than men with obesity, highlighting sex-related differences [15].

Apolipoprotein B-100 Apolipoprotein B-100 (APOB) is a major protein constituent of LDL. Increased levels of this molecule are well established to be solid predictors for cardiometabolic events [33]. In this regard, recent studies reported that higher levels of APOB were a good risk predictor for long-term cardiovascular events in patients with obesity [34]. Moreover, increased abundance of this protein in patients with obesity were decreased by bariatric surgery, revealing the role of this intervention in reducing levels of APOB and decreasing risk of cardiometabolic diseases [35]. In addition, increased levels of APOB were found in plasma and VAT from patients with obesity compared to normo-weight individuals revealing it concerning and important role in cardiometabolic health outcomes of patients with obesity [15, 36].

ATP Synthase Subunit Beta ATP synthase subunit beta (ATP5F1B) is a target enzyme for human health that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. Malfunction of this complex has been implicated in a wide variety metabolic disease. ATP5F1B plays a beneficial role in obesity-induced non-alcoholic fatty liver disease (NAFLD) by improving mitochondrial function in hepatic steatosis [37]. Inhibition of this enzyme could alter energy and lipid

metabolism, contributing to an insulin resistant phenotype and to the onset and progression of T2DM [38]. In addition, an impaired ATP5F1B translation has been correlated with the suppression of muscle metabolism in SKM of individuals with obesity compared to lean subject [39]. ATP5F1B abundance was increased in SAT samples from insulin-resistant patients with obesity compared to lean insulin-sensitive controls [40], demonstrating an important role in the development of obesity-related IR and inflammation due its involvement in energy and free fatty acid metabolism. In accordance with this result, ATP5F1B was also increased on SAT from individuals with morbid obesity compared to lean subjects, supporting those metabolic differences in both groups [25].

Creatine Kinase B-Type Creatine kinase B-type (CKB) is a cytoplasmic enzyme involved in energy homeostasis. It reversibly catalyses the transfer of phosphate between ATP and various phosphagens, playing a central role in energy transduction in tissues with large and fluctuating energy demands as AT [41]. Moreover, CKB abundance is strongly induced by thermogenic stimulation in adipocytes. In this regard, recent studies in obesity reported that inactivation of CKB in adipocytes decrease thermogenic capacity, highlighting the important role of BAT in energy expenditure by generating heat through this process [42]. Decreased levels of CKB abundance were found on SAT and VAT of individuals with obesity compared to lean subjects [25, 43]. Shang et al. revealed a downregulation of CKB in VAT of women with morbid obesity who underwent bariatric surgery compared to normoweight females who underwent elective abdominal surgical procedures [43]. Those results are consistent with Benabdelkamel et al. who also reported a decreased abundance of CKB on SAT from patients with morbid obesity, but also in individuals with overweight compared to lean controls [25].

Dihydropyridyllysine-Residue Succinyltransferase Dihydropyridyllysine-residue succinyltransferase (DLST) is a component of one of the rate-limiting enzyme complexes in the tricarboxylic acid cycle, playing a role in carbohydrate metabolism [44]. DLST has been reported to contribute to energy expenditure by enhancing the mitochondrial lipoylation pathway [45]. In this regard, DLST protein abundance was found increased in platelets of individuals with obesity compared to controls [46], while a decreased abundance of this protein was reported in subjects with obesity by Kras et al. and Boden et al. in SAT and SKM [24, 26].

D-Lactate Dehydrogenase D-lactate dehydrogenase (LDHD) is a mitochondrial protein that catalyses specifically the reduction of D-lactate to pyruvate with concomitant oxidation of NAD⁺ to NADH [47]; it may play a role in regulating

apoptosis, cell proliferation and cell differentiation, serving as a general indicator of acute and chronic diseases [48]; however, there is not much evidence available associating altered abundance of this protein in individuals with obesity. In contrast, LDHD was found decreased in VAT and SKM from individuals with obesity [26, 43]. These findings, thus, suggest that downregulation of this mitochondrial protein could have a potential role as a biomarker in obesity and its associated metabolic diseases.

Glyceraldehyde-3-Phosphate Dehydrogenase Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) modulates the organization and assembly of the cytoskeleton. It is one of the central enzymes in glycolysis, generating NADH, which is a source of energy and metabolites for several diseases [49]. Altered GAPDH expression in human muscle has been associated with IR and a tendency towards a higher lipogenic gene expression, which are associated with obesity phenotype [50]. In addition, significant increased abundance of glycolytic enzymes, including GAPDH, were found in women with obesity or morbid obesity, relative to lean control subjects. It was reported an increased protein abundance of GAPDH in SKM of individuals with obesity compared to lean patients [51, 52]. These alterations may balance the progressive decrease in muscle mitochondrial function of individuals with obesity, contributing to the loss of glucose and lipid homeostasis over time, and to the eventual development of obesity-related diseases such as T2DM. In contrast, a low abundance of GAPDH was found in platelets of individuals with obesity compared to lean patients [22]; however, limitations of the study, including number and gender of individuals analysed should be considered.

Malate Dehydrogenase, Cytoplasmic Malate dehydrogenase (MDH1) catalyses the interconversion of malate and oxaloacetate in the mitochondrial membrane, playing an indispensable role in ATP generation [53]. It represents a source of energy in differentiated cells, supporting proliferation and glucose consumption, but also acting as a prognostic biomarker in some life-threatening situations [53]. Previous studies in obesity reported that acetylation levels of MDH1 are significantly increased during adipocyte differentiation [53, 54]. Adipocyte differentiation can contribute to the development of obesity via a positive energy balance. Interestingly, increased levels of MDH1 in adipocytes induce enhanced adipogenesis in these cells, increasing its enzymatic activity [54]. These findings contrast with Grande et al. and Giebelstein et al. who reported decreased abundance of this enzyme in platelets and SKM of individuals with obesity [52, 55]. In this line, decreased levels of MDH1 are related to metabolic disorder of the malate–aspartate shuttle as well as disruption in several pathways, which may indicate that the decrease in MDH1 and subsequent

reduction in the NAD/NADH is a likely mechanism of cellular aging controlled by carbohydrate metabolism [52, 55].

Mitochondrial Pyruvate Carrier-1 Mitochondrial pyruvate carrier-1 (MPC1) is a key metabolic protein that regulates the transport of pyruvate into the mitochondrial inner membrane [56]. It is critical for several major biological pathways of carbohydrate, lipid, and amino acid metabolism, providing energy [57]. Moreover, it has emerged as a promising pharmacological target for metabolic disorders by modulating mitochondrial function [58]. MPC1 abundance was found decreased in several kind of samples of individuals with obesity, including SKM or sperm [21, 26], suggesting that a decrease in MPC1 may promote dysfunctional mitochondria metabolism in obesity.

Phosphatidylinositol 5-Phosphate 4-Kinase Type-2 Alpha Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha (PIP4K2A) is a protein implicated in lipid metabolism, including various aspects of intracellular cholesterol transport [59]. Barrachina et al. and Grande et al. both identified decreased abundance of PIP4K2A in platelets of individuals with obesity compared to normoweight controls [22, 46]. Platelets are key players in the pathophysiology of several diseases related to obesity [60], and their function and size have been reported to be altered in obesity [61]. Decreased abundance of PIP4K2A in these cells suggests that PIP4K2A could be responsible at least in part for the platelet alterations observed in obesity [46].

Pyruvate Kinase Pyruvate kinase (PKM) is an enzyme that catalyses the conversion of phosphoenolpyruvate and ADP to pyruvate and ATP in glycolysis. It plays an essential role in regulating cell metabolism [62]. Recent evidence suggests the involvement of this enzyme modulators in several metabolic diseases. PKM may regulates gene activation in the context of inflammation and metabolic reprogramming, being a promising target for addressing some pathologies, including obesity [63]. An increased abundance of this metabolic protein was reported by Kras et al. in SKM of individuals with obesity [26]. However, a previous proteomics study in obesity reported decreased levels of PKM in the same tissue of individuals with obesity compared to lean controls [51]. This could be explained by differences in muscle location of patients. Hittle et al. reported a decreased abundance of PKM in SKM [51], while Kras et al. reported an increased abundance of this protein in collected biopsies from the vastus lateralis muscle [26]. In addition, Grande et al. reported decreased levels of PKM in platelets of patients with obesity [55].

Proteins Related to Chaperon Binding Proteins that facilitate the folding of other proteins are called chaperones. Chaperones are a broad class of proteins that maintain protein

homeostasis by monitoring the quality and integrity of protein structure. They have the potential to prevent non-specific aggregation by binding to non-native proteins and assist in protein folding [64]. Protein folding is a process that usually takes place in the ER, eliciting proper forming of proteins [65]. Given the growing body of research indicating the involvement of ER stress in various disease pathologies, including obesity, the concept of enhancing ER folding capacity through chemical chaperones has emerged as a promising therapeutic strategy, especially in the context of metabolic disorders [66]. Most of chaperon binding proteins abundance have been found to be increased in individuals with obesity compared to normoweight matching controls (Table 3) except for 2, that have been found increased/decreased in different studies and 1 that have shown a consistent decrease.

Albumin Albumin (ALB) is the most abundant extracellular chaperone protein. ALB is the most significant modulator of colloid osmotic-pressure and transports a large variety of molecules such as fatty acids, drugs or hormones. Moreover, it acts as an antioxidant agent [67]. Values of serum ALB has been reported to be decreased in obesity. This state of inflammation may lead to altered ALB levels among the population with obesity compared to healthy controls, making this condition an independent predictor of hypoalbuminemia [68]. In addition, ALB concentration was positively associated with the prevalence of metabolic syndrome (MetS), whereas an increase in ALB over time might protect against MetS development [67]. ALB abundance was found increased in several samples including, platelets, SAT or SKM proteome of individuals with obesity compared to normoweight matching controls. Differentially altered ALB abundance thus, may point to increase according to BMI [25, 46, 51].

Crystallin B Chain, Alpha Crystallin B chain alpha (CRYAB) is one of the most widespread and represented of the human small HSP. CRYAB prevents aggregation of various proteins under a wide range of stress conditions. It is greatly expressed in tissues with high rates of oxidative metabolism, such as skeletal and cardiac muscles [69]. Dysfunctions of this protein are associated with several metabolic diseases due to its important role in protection of muscle tissues from the alterations of protein stability [69]. Increased levels of CRYAB in the obesity as well as in weight regain after long-term weight loss maintenance have been demonstrated previously [30, 70], supporting the role of CRYAB in obese phenotype. These results are consistent with our findings. Benabdelkamel et al. and Boden et al. revealed high abundance rates of CRYAB on SAT of individuals with obesity compared to normoweight controls [24, 25]. This could influence weight management, revealing CRYAB as a biomarker of obesity and a mediator of weight control.

Endoplasmic Reticulum Chaperone BiP Endoplasmic reticulum chaperone BiP (HSPA5) is a molecular chaperone involved in the correct folding and assembly of proteins, and in the degradation of misfolded proteins in the endoplasmic reticulum (ER). HSPA5 is a master regulator of ER homeostasis and functions, and it is an essential component of the protein translocation machinery into the endoplasmic reticulum (ER) [71]. Previous studies have reported that HSPA5 abundance was increased in AT of patients with obesity highlighting its direct association between BMI and other metabolic factors including IR or hypertriglyceridemia [72]. In this regard, Benabdelkamel et al. reported higher abundance of HSPA5 on SAT of individuals with obesity compared to lean controls [25]. On the other hand, Grande et al. identified a lower abundance of HSPA5 in platelets of individuals with obesity compared to lean subjects [55]. Those differences in protein abundance may indicate that HSPA5 role in obesity need to be further investigated, however, limitations of studies, including small number of individuals analysed or sex-related differences should be considered [25, 55].

Heat Shock Protein Beta 1 Heat shock protein beta 1 (HSPB1) is a ubiquitous chaperone involved in key physiological and cellular pathways such as inflammation, immunity or apoptosis [73]. It also mediates the survivability of the cells under various stressful conditions, as it is able to control the redox state of the cell [74]. Previous studies in obesity showed a direct association between HSPB1 abundance and BMI, or high levels of HSPB1 and IR, suggesting an important role in metabolic disorders [75]. In addition, Boden et al. reported a higher HSPB1 abundance in SAT proteome of individuals with obesity compared to lean controls, supporting those previous findings [24]. However, results of Barrachina et al. and Benabdelkamel et al. reported a downregulation of this protein in platelets and SAT of patients with obesity, respectively [25, 46].

Heat Shock Protein Beta 6 Heat shock protein beta-6 (HSPB6) plays an essential role as molecular chaperones in proteostasis and cell growth and survival [74]. Heat shock proteins (HSP) are produced in response to multiple stressors [76]. HSPB6 is the most upregulated HSP protein during differentiation of human adipose-derived stem cells into mature adipocytes [77] and it has been reported to be a negative regulator of adipocyte function [78]. Benabdelkamel et al. and Boden et al. revealed an increased abundance of HSPB6 on SAT of individuals with obesity [24, 25].

Protein Disulfide-Isomerase A3 Protein disulfide isomerase A3 (PDIA3) is a chaperone protein that modulates protein folding of newly synthesized glycoproteins and responds to endoplasmic reticulum (ER) stress [79]. Previous studies

in obesity showed that circulating levels of PDIA3 were increased in pediatric subjects with obesity compared to controls. PDIA3 circulating levels were positively associated with obesity markers, IR and LDL-cholesterol. This is evidence that PDIA3 could be an early marker of IR, dyslipidemia and other obesity-related complications [80]. Those results match similar studies in adult population, emphasizing the role of PDIA3 in obesity [81]. Moreover, downregulation of PDIA3 abundance was also reported in two independent proteomics analyses selected for the present systematic review, including samples of SAT and platelets in individuals with obesity compared to lean patients [24, 55].

Proteins Related to Coagulation Cascades Obesity is characterized by the elevation of several clotting factors and PAI-1 directly affecting coagulation [82]. The involvement of adipose tissue to increase the thrombotic tendency has been proposed through several mechanisms involving platelet function abnormalities and increased coagulation, together with endothelial dysfunction [82, 83]. No proteins related to coagulation cascades have shown a consistent decrease in subjects with obesity as compared to their normal-weight counterparts, while 3 proteins were found to be increased and 4 proteins were found increased/decreased in different studies as it is reported in Table 3. This may suggest that alterations in abundance of coagulation cascades proteins have an important role in obesity as they can modulate several metabolic disorders [84].

Annexin A5 Annexin A5 (ANXA5) is the most abundant annexin and it is expressed ubiquitously. It has an anticoagulant function and a potential role in cellular signal transduction, inflammation, and differentiation [85]. Moreover, it appears to play a role in triglyceride metabolism [86]. ANXA5 protein was induced in adipocytes during aging [87] and one study demonstrated an association of ANXA5 polymorphisms with obesity in a Korean patient cohort [88], which may suggest a function of ANXA5 on the fat deposition, storage or mobilization. Barrachina et al. and Benabdelkamel et al. reported increased levels of ANXA5 in platelets and SAT of individuals with obesity compared to lean healthy controls [25, 46]. As it is stated, higher abundance of ANXA5 in proteome of individuals with obesity may be associated with the development of obesity and could mediate in some coagulation disorders related to this condition [88].

Coagulation Factor V Coagulation factor V (F5) is the central regulator of haemostasis. It plays an important role in the propagation phase of coagulation as a component of the prothrombinase complex [89]; however, it mediates both procoagulant and anticoagulant functions as a result of the activity of proteases [90]. Alterations in coagulation have

been widely studied in obesity. A recent study comparing individuals with obesity and normoweight controls showed that BMI contributes to hypercoagulability, highlighting those individuals with obesity are more hypercoagulable [91]. F5 activity was found to be statistically insignificant in plasma of patients with obesity compared to control [92], which is consistent with Barrachina et al. [46]. They both reported decreased abundance of this protein in plasma of individuals with obesity, highlighting its role in cardiovascular events in obesity [46]. However, Grande et al. showed that F5 was increased in platelets from patients with obesity compared to non-obese controls [55].

Fibrinogen Fibrinogen plays key roles in both blood clotting and platelet aggregation. Fibrinogen is a hexameric plasmatic glycoprotein composed of pairs of three chains: fibrinogen alpha chain, fibrinogen beta chain (FGB) and fibrinogen gamma chain (FGG). The most significant biological role of fibrinogen is related to its ability to form the scaffold of a blood clot and prevent the loss of blood after injury [93]. However, fibrinogen together with fibrin plays important and overlapping roles in fibrinolysis, cellular and matrix interactions and inflammation [93]. Several studies have reported higher plasma fibrinogen levels in subjects with obesity. More specifically, FGG has been found increased in women and children with obesity [94]. Protein abundance of FB and FGG were reported to be increased in several tissues, including EVs, platelets and SKM, of patients with obesity compared to lean individuals in three independent studies [52, 95].

Haemoglobin Haemoglobin (Hb) is an iron-containing metalloprotein that transports oxygen molecules from the lungs to the rest of the human body. Haemoglobin consists of protein subunits haemoglobin subunit alpha 1 (HBA1) and alpha 2 (HBA2), and haemoglobin subunit beta (HBB) [96]. Circulatory Hb levels have been reported to be increased in patients with obesity [97]; however, another study reported not differences [98]. In this regard, HBA1 and HBB were found to be decreased in serum proteome of metabolically abnormal individuals with obesity compared to controls [99]. However, different abundance of both subunit proteins was variable depending on the analysed sample selected. Barrachina et al. reported a decrease of HBA1 and HBB in EVs of women with obesity compared to normoweight controls [46], while an increase of both proteins was found on SAT and SKM in three other independent studies [25, 51, 52].

Integrin Alpha-IIb Integrin alpha-IIb (ITGA2B) is a highly abundant heterodimeric platelet receptor that can transmit information bidirectionally across the plasma membrane and plays a critical role in haemostasis and thrombosis and

platelet aggregation [100]. ITGA2B levels were reported to be reduced in platelet particles from subjects with obesity using flow cytometry [55]. Two studies of the present systematic review found contradictory ITGA2B protein abundance results in obesity. Grande et al. reported a decrease of ITGA2B abundance in platelets of woman with obesity compared to lean matching controls [55]. However, Barrachina et al. found that ITGA2B was increased in patients with obesity compared to lean healthy controls [46]. These contradictory results may be a result of the effect of sex.

Proteins Related to Structure/Cytoskeleton Seven proteins related to structure/ cytoskeleton have shown altered abundance in subjects with obesity as compared to their normal-weight matching controls. Two of them have shown a consistent increase, while 5 proteins were found increased/ decreased in different studies. Any of the analysed studies reported a consistent decrease of these types of proteins. This suggests the significant role in adipose tissue growth of proteins related to structure/ cytoskeleton as they are involved in both hypertrophy and hyperplasia of fat cells.

Actin, Cytoplasmic 1 Actin (ACTB) is the most abundantly expressed protein in eukaryotic cells and is the key building block of the filamentous actin cytoskeleton. It is an essential component for almost all actin-dependent cellular processes, including cell migration, cell cycle progression, chromatin remodelling and gene expression and DNA damage response [101]. ACTB has been used as a reference protein/gene in many studies including those for obesity studies [102]. However, proteomics studies reported in the present systematic review found altered abundance of ACTB protein in obesity. While Barrachina et al. reported an increase in ACTB abundance in subjects with obesity compared to lean individuals, Grande et al. and Hittle et al. reported a decreased ACTB abundance in platelets and SKM of patients with obesity, respectively [22, 46, 51].

Desmin Desmin (DES) is a muscle-specific intermediate filament protein and a key subunit of the intermediate filament in cardiac, skeletal, and smooth muscles [103]. It plays a critical role in the maintenance of sarcomeres structures, forming the myofibrils, and in mechanical integrity of the contractile apparatus in muscle tissues [103]. Previous studies showed that DES deletion is associated with mitochondrial dysfunction in muscle cells, which may result in altered metabolism and therefore, alter muscle function [104]. Moreover, DES has a strong association with the development of some cardiometabolic diseases, including obesity [56, 105]. Giebelstein et al. reported increased expression of DES in SKM of individuals with obesity compared to lean controls [52]. However, a previous proteomics study describing differences in proteins abundance related to obesity in

the same tissue revealed decreased abundance of DES in individuals with obesity compared to lean controls [106].

Gamma-Synuclein Gamma-synuclein (SNCG) is an adipocyte-neuron gene with several implications in metabolic health due to its high abundance in white adipose tissue (WAT) [107]. In addition, SNCG plays an important role in adipocyte physiology. Previous studies in obesity reported that SNCG is highly expressed in human WAT and increased in obesity. Oort Pieter et al. reported that upregulation of SNCG is nutritionally regulated in WAT whereas its loss partially protects from high-fat diet induced obesity and ameliorates some of the associated metabolic complications, highlighting the role of SNCG overexpression in obesity [107]. In this regard, decreased levels of this protein in human have been correlated with protection against obesity following high fat diet [108]. Those findings are consistent with Boden et al. and Shang et al., who described an increased abundance of SNCG in both SAT and VAT of individuals with obesity compared to lean controls [24, 43].

IgGFC-Binding Protein IgGFC-binding protein (FCGBP) is one of the core mucus proteins which are produced and secreted by goblet cells, which has an essential role in protection of epithelial surfaces or mucosal defence. A recent meta-analysis reporting AT epigenetic profile in obesity showed that FCGBP gene is hypomethylated in metabolically unhealthy individuals with overweight or obesity [96]. This protein is expressed in mucin secreting cells in tissues such as the colon, small intestine or gall bladder, providing an anti-inflammatory function which may confer some protection against the obesity induced low-grade inflammatory state [96]. FCGBP protein abundance was found increased in endometrial tissue of women with obesity compared to normoweight matching controls but decreased in EVs of a similar population of women with obesity [46, 109].

Myosin Light-Chain Polypeptide-6 Myosin light-chain polypeptide-6 (MYL6) is a hexameric ATPase cellular motor protein. It mediates airway smooth muscle contractile function, which is related to asthma due to the excessive airway narrowing produced by an increase in contractility of this tissue. This contractile response is reported to be enhanced in obesity [110]. MYL6 has been associated to metabolic alterations [111]. Previous studies in animals reported an upregulation of MYL6 in lung tissue of obese mice compared to lean control after a nutritional intervention based on a high fat diet [112]. Moreover, higher differences in MYL6 gene expression were found in placenta of pregnant women with obesity compared to lean matching controls [113]. In the present review, it was found that Boden et al. reported an increased abundance of MYL6 on SAT of individuals with obesity [24], while Grande et al. described a decreased

abundance of MYL6 in platelets of women with obesity compared to lean controls [55]. Differences in MYL6 abundance may be explained by the tissue sample or by the gender analysed.

Tropomyosin Alpha-1 Chain Tropomyosin alpha-1 chain (TPM1) is an actin-binding protein involved in the contractile system of striated and smooth muscles and the cytoskeleton of non-muscle cells. Mutations in this gene have been associated with physio pathological process related to several cardiometabolic diseases, such as obesity [114]. A recent study reported that expression level of TPM1 was decreased in subjects with obesity after a high-fat diet, while it was increased after an antioxidant intervention due to a reduction in process mediated by oxidative stress [115]. Therefore, it was suggested that obesity may damage the structure and function of the heart by down-regulating TPM1 expression. Conflicting proteomics results have been reported, while Grande et al. reported a decrease of TPM1 abundance in platelets of individuals with obesity compared to lean controls [55], Barrachina et al. reported an increase of TPM1 abundance in platelets of subjects with obesity [46].

Vimentin Vimentin (VIM) is an abundant cytoplasmic protein which is recognized for its important role in stabilizing intracellular structure and its mechanical role in cell plasticity and stress absorbers [116]. VIM is expressed in mesenchymal origin, including adipocytes where it forms lipid droplets and stabilizes triglycerides [117]. Moreover, VIM participates in lipolysis through direct interactions with hormone-sensitive lipase [118]. In this regard, previous studies reported that a lack of VIM results in less fat accumulation [119]. In addition, it has been pointed out that VIM deficiency prevents high-fat diet-induced obesity [120]. Those findings are in the same direction of proteomics study results. Boden et al. and Benabdelkamel et al. both reported an increased abundance of VIM on SAT of individuals with obesity [24, 25].

Proteins Related to Inflammation and Oxidative Stress Chronic low-grade inflammation has been increasingly recognized to be involved in the pathophysiology of metabolic disease such as obesity [121]. Moreover, it is known that obesity promotes oxidative stress by producing oxidants and reducing antioxidant levels, contributing to the development of obesity-related complications [122]. Four proteins related to inflammation and oxidative stress have shown a consistent increase in subjects with obesity as compared to their normal-weight counterparts, while 2 proteins were found to be increased/decreased and only 1 protein was found to be consistent decreased in different studies.

Amyloid P-Component, Serum Amyloid P-component, serum (APCS) is an acute phase protein made by the liver and

secreted into the blood which regulates several aspects of the immune system [123]. Elevated levels of this protein in obesity have been reported, accompanied by a positive correlation with BMI and risk of cardiovascular diseases [124]. However, the role of APCS in human obesity has not been clearly elucidated. Studies may indicate that levels of this protein are elevated compared with non-obese controls but, in contrast, this may be a mechanism to down-regulate the effects of obesity, rather than a cause of obesity [125]. According to our results, APCS abundance have been found upregulated in plasma and EVs of individuals with obesity compared to lean controls, suggesting that this protein abundance may be the result of adaptation of the organism to the low-grade chronic inflammatory that underlies severe obesity [14, 46].

Catalase

Catalase (CAT) is an essential antioxidant enzyme that protects cells against cellular toxic effects mediated by removing reactive oxygen species [126]. The antioxidant activity of CAT is significantly diminished in adults with obesity [122]. However, increased abundance of CAT, together with other proteins related to metabolic pathways has been associated with human AT protection and insulin-stimulated glucose uptake improvements in obesity [127]. Decreased levels of CAT were found in patients with morbid obesity after bariatric surgery [126]. Moreover, a significant decrease in abundance of CAT was found in patients with morbid obesity comparing to lean controls, additionally pointing to decrease in lipolysis within the mature adipocytes of SAT of this population [25]. In this regard, Kras et al. reported a decrease in CAT abundance in SKM proteome of subjects with obesity compared to controls [26]. Accordingly, upregulation of CAT may promote insulin sensibility and protect against obesity by influencing energy expenditure processes [25, 26].

Complement C3

Complement C3 (C3) is part of the complement system, a complex enzymatic cascade consisting of more than 50 circulating and cell surface proteins working in cascades of stepwise protease activation, playing an important role as component of immune system [128]. C3 is a fundamental factor in metabolic organs and metabolic diseases, affecting insulin secretion and adipocyte maturation [129]. Moreover, previous studies have shown altered complement system in obesity, where excessive activation of the classic pathway of complement commonly occurs [130]. Increased C3 abundance was found increased in 2 independent studies of the present systematic review comparing EVs and plasma of individuals with obesity and lean controls and revealing the role of C3 in as an early marker for obesity and some related cardiovascular diseases [14, 46].

Galectin-1

Galectin-1 (LGALS1) is a carbohydrate-binding protein that plays key immune regulatory roles in autoimmunity and chronic inflammation [131]. Moreover, it plays a role in a variety of cell functions including interferes with cell adhesion, proliferation, differentiation and angiogenesis [132]. LGALS1 is expressed in many tissues under normal and pathological conditions. Its abundance has been reported to be increased in obesity, both in the circulation and in the AT [133]. Moreover, LGALS1 expression has been reported to be decrease in participants with obesity during weight loss while increased during weight gain [133]. In this regard, LGALS1 was found increased on SAT of individuals with obesity in two different studies in the present systematic review [24, 25].

Glutathione-S-Transferase P

Glutathione-S-transferase P (GSTP1) is an antioxidant enzyme involved in the formation of prostaglandins [134], with a catalytic detoxification role through inactivating byproducts of oxidative stress [135]. Previous studies have reported the association between GSP1 and some metabolic disorders [136]. Moreover, a positive correlation between GSTP1 polymorphism and obesity was observed on young adults with obesity, revealing its significant role in the increase of susceptibility of obesity and cardiovascular risk in this population [137]. Individuals who carry less efficient alleles of detoxification enzymes GSTP1 are subject to lower production or inefficient activity of these detoxification enzymes, which favours the development of obesity [137]. These findings are consistent with Boden et al. who reported upregulation of GSTP1 in VAT of patients with obesity compared to healthy controls [24]. In contrast, the abundance of GSTP1 was decreased in platelets from patients with obesity compared to individuals without obesity [55], which may also increase the production of oxidative agents and pro-inflammatory mediator in some cases [138].

Lysozyme C

Lysozyme C (LYZ) is a component of the innate immune system that exerts anti-microbial effects through the hydrolysis of bacterial cell wall peptidoglycan [121]. It is considered as an important contributor to chronic low-grade inflammatory state. However, although it is important for driving a pro-inflammatory response, LYZ also plays a role in limiting inflammation system [139]. Decreased expression of LYZ was found in intestine of subjects with obesity [140]. Moreover, LYZ levels in plasma were significantly increased in obesity in direct link with obesity-associated metabolic disturbances and inflammatory parameters [121]. LYZ abundance was found decreased




Fig. 2 Enrichment analysis-GO: biological process

in circulating samples including platelets or plasma of patients with obesity compared to lean control [15, 46]. In contrast, a recent proteomics approach in obesity included in systematic review showed an increased protein abundance of LYZ in VAT of subjects with obesity compared to VAT of normoweight patients [43].

Parkinson Disease Protein-7

Parkinson disease protein-7 (PARK7) is a multifunctional protein that has been described as a modulator of adipogenic differentiation and as a modulator of immune and inflammatory regulatory functions in many tissues [141]. Moreover, PARK7 has been reported to protect cells from oxidative stress injury. Animal studies have shown that raised PARK7 is correlated with obesity [142]. Conversely, PARK7 knockout mice had protection from diet to become obese. However, their inherent metabolic propensities and experimental outcomes towards obesity were influenced by strain differences, age, the effects of different high-fat diet composition and feeding period [142]. In addition, some other proteomics studies in obesity suggests that PARK7 are a proper reference standard in obesity studies based on VAT [143]. PARK7 protein abundance was found increased on SAT and SKM of individuals with obesity [25, 26].

Enrichment Analysis Databases resources Gene ontology (GO) and Kyoto Encyclopedia of Gene and Genomics (KEGG) were employed for the enrichment analysis of identified proteins in obesity. A systematic research of gene functions, linking genomic information with higher order functional information of proteins was conducted, including molecular function (MF), biological processes (BP) and cellular components (CC), as it is shown in online resource 2. The most significant results from the enrichment analysis of BP reveal that oxidative stress and haemostasis, including coagulation and platelet activation, were the most prevalent process (Fig. 2). Moreover, the molecular function enrichment analysis showed that the most relevant molecular functions were related to oxidative stress, metabolism and structural and protein folding (Fig. 3).

Discussion

We have conducted an extensive systematic review of non-targeted proteomics studies in human obesity, identifying common trends in protein abundance profiles across various biological samples. A significant amount of knowledge has been gained in the last 2 decades on the proteomic profile of obesity. The application of proteomics




Fig. 3 Enrichment analysis-GO: molecular functions altered in patients with obesity compared to normweight individuals

represents a crucial approach in the management of obesity. This methodology has the potential to identify proteins involved in pathological processes and to evaluate changes in protein abundance during obesity development, contributing to the identification of early disease predisposition, monitoring the effectiveness of interventions and improving disease management overall. Additionally, it holds significant importance in drug development as proteomics identifies potential target molecules. Moreover, it can provide valuable insights into post-translational protein modifications, protein–protein interactions and signalling in obesity [144]. Proteomics can thus contribute significantly to our understanding of the complex interplay of proteins involved in obesity-related processes, offering potential targets for therapeutic interventions and personalized treatment strategies. The escalating global obesity epidemic represents one of the most serious public health challenges as the prevalence of obesity is increasing worldwide [145]. According to the World Health Organization (WHO), five million people die each year as a result of excess weight [https://www.who.int]. The alarming worldwide incidence increase of obesity is also associated with an array of metabolic pathologies, including T2DM and cardiovascular disease, spurring intense research efforts to understand the mechanisms underlying these disorders.

Although the results of such efforts have led to the development of new treatment options, these conditions remain among the leading causes of global mortality and morbidity, emphasizing the need for more effective therapeutic and preventive measures. Existing trends indicate that the scope of the problem is only likely to grow, especially in rapidly developing parts of the world. Many contributing agents have now been identified, including genetic, dietary and environmental factors. However, the mechanisms by which excess nutrients and adiposity can ultimately result in one or more of a large cluster of chronic diseases are still being elucidated. Understanding the role of proteins in the onset and progression of obesity is crucial in medical research. This knowledge could significantly contribute to the effective management of obesity, reducing associated risks and improving overall health outcomes and quality of life of patients. It is essential to provide a fundamental basis for an accurate and comprehensive therapeutic approach to obesity. Such research can inform and enhance the efficacy of obesity management therapies. Our systematic review offers valuable insights into the proteomics field in obesity with significant implications for the understanding of protein regulation and biomarker discovery, and therefore contributing to open new pathways for personalized medicine of obesity.

One of the primary achievements of this systematic review is the integration of proteomics data from multiple samples and analytical platforms. Our approach has involved harmonizing the data to identify consistent patterns in protein abundance and variation across different studies. Such integration provides a framework for future studies. In order to obtain more robust results, we focused on those proteins that were found in at least 2 proteomics studies. Figure 4 shows a comprehensive view of all the included proteins in the present systematic review, including functional processes mediated by them and human samples where have been found altered. Those proteins, forty-one, were related to several functions such as coagulation, inflammation/oxidative stress, metabolism, protein folding and structure/organization. All these processes have been reported to be altered in obesity.

Our analysis has revealed that the most altered proteins in obesity were predominantly involved in various aspects of metabolism, reflecting the intricate dysregulation of metabolic pathways associated with this condition. These findings are further supported by the enrichment analysis, which suggests an alteration in catabolic and metabolic processes in obesity (Figs. 2 and 3) and underscore the multifaceted nature of metabolic dysregulation in this condition [16]. Specifically, 13 proteins related to metabolic pathways were found altered in subjects with obesity. These proteins play crucial roles in maintaining energy homeostasis and facilitating ATP generation, essential processes for cellular function and overall energy balance [24, 25]. Other notable pathways affected were lipogenesis, the synthesis of fatty acids and triglycerides,

which is altered in obesity due to excessive nutrient intake and adipose tissue expansion [51, 52]. Additionally, our research highlighted alterations in proteins involved in the metabolism and transport of lipoproteins, critical for lipid transport and cholesterol homeostasis [15, 25]. Proteins involved in gluconeogenesis, the synthesis of glucose from non-carbohydrate precursors, are also dysregulated in obesity, being the result or contributing to disturbances in glucose metabolism and insulin resistance in this pathology [51, 52]. Moreover, there are advances in pharmacological therapies targeting metabolic proteins. Studies have shown that some metabolic proteins could have a potential use as biomarkers of weight regain [146], as well as pharmacological therapy for metabolic diseases [147]. Therapies that modulate the activity of ATP synthase have been explored to treat metabolic disorders [148]. On the other hand, it has been studied the increase of creatine kinase B (CKB), known to promote thermogenesis, has been investigated as a potential approach to counteract obesity [41, 149]. Enzymes of gluconeogenesis and glycolysis (such as glucose-3-phosphate dehydrogenase or pyruvate kinase [PK]) have been considered as potential targets for the treatment of metabolic disorders such as T2DM [150]. One important drug, metformin, which is an inhibitor of one isoform of PK, has been widely used to counteract glucose levels in diabetic patients [151]. Furthermore, there are also therapies that modify the levels or functions of apolipoproteins with the aim of treating cardiovascular diseases and cholesterol-related metabolic disorders [152].

Oxidative stress constitutes a distinctive hallmark of obesity [153]. Our systematic review reveals several altered




Fig. 4 A summary of proteins altered in individuals with obesity compared to normweight patients

antioxidants, key proteins associated with oxidative stress, in the proteome of individuals with obesity. These proteins consistently display a decrease in antioxidant activity in most of the studies. It is well-known that obesity promotes oxidative stress by producing oxidants and reducing antioxidant levels, contributing to the development of obesity-related complications, such as cardiovascular disease, insulin resistance and metabolic syndrome, among others [122]. Moreover, the enrichment analysis showed that many of the proteins reported in the present review are also involved in oxidative stress in several processes, such as process and response to hydrogen peroxide and reactive oxygen species, and cellular oxidant detoxification (Figs. 2 and 3). Furthermore, obesity is considered as a chronic low-grade systemic inflammation associated with increased inflammatory markers [154]. This inflammation also contributes to associated alterations in obesity. We found 4 proteins involved in inflammation altered in obesity, where most of the studies reported an increased abundance and the enrichment analysis showed some proteins involved in the regulation of acute inflammatory response. Establishing an inflammatory phenotype could be useful in classifying individuals at risk. Cross-sectional studies have consistently demonstrated that anti-inflammatory nutrients are associated with lower levels of inflammatory markers [155] and pharmaceutical agents have targeted inflammatory pathways as potential therapeutic avenues for T2DM [155]. Numerous studies have evaluated the positive effect of antioxidant supplements in obesity and associated metabolic disease by improving glycaemic control and lipid profile, oxidative stress and inflammation [156]. Moreover, there are several antioxidant enzyme mimics currently under exploration, with some actively undergoing clinical trials [157].

Our analysis identified 6 proteins involved in protein folding that were altered in obesity and the enrichment analysis showed that protein folding was a prevalent function performed by the identified proteins. Protein folding is a process that usually takes place in the endoplasmic reticulum, eliciting proper forming of proteins [70], and actively participating in the protein homeostasis of the cells. It is considered as a vital cellular process because proteins must be correctly folded into specific, three-dimensional shapes in order to function correctly [158]. Unfolded or misfolded proteins contribute to the pathology of many diseases, such as obesity and cardiometabolic related disease [159]. Moreover, previous studies have reported strong correlations between chaperones with greater food intake or weight regain percentage [146, 160]. In addition, human and animal studies have shown that pharmaceutical chaperones, which are small molecules designed to stabilize the folding of proteins, improve insulin sensitivity in subjects with obesity [161]. Therefore, future studies on the six proteins involved in protein folding reported in this systematic review could

contribute to elucidate mechanism of action in obesity development and to progress in the therapeutic avenue of it.

Several structural proteins have been reported to be altered in obesity. It is well-known that obesity is characterized by the induction of several tissue remodelling and, therefore, it is not surprising to find altered structural proteins in different tissues, such as AT and SKM from patients with obesity. Moreover, structural proteins were found altered in platelets. Obesity alters platelet number, morphology and activity [162], and altered structural proteins could be part of as a result of these processes. Platelets are a pivotal component of the physiologic haemostatic balance, which is also maintained through coagulation pathway. It has been found that regulating platelet function is beneficial. For individuals with obesity, exercising can help regulate platelet function and haemostasis. When engaged in moderate-intensity exercise, platelet aggregation and clotting factors are reduced, which can potentially decrease the risk of thrombosis [163]. The proteins described in this context could be used to design monitoring panels for platelet modulation. Furthermore, obesity exerts significant effects on the coagulation system. Seven proteins with pivotal roles in coagulation processes were altered in individuals with obesity. Derangements of blood coagulation has been reported previously in obesity several times [164], describing obesity as a promoter of coagulation. The enrichment analysis showed a high prevalence of proteins involved in haemostasis, coagulation and platelet aggregation and activation. As circulating proteins involved in haemostasis, coagulation and platelet aggregation are indicative of the underlying pathological mechanisms occurring in obesity, their concentrations could serve as potential biomarkers for stratifying the risk of comorbidities associated with obesity. Utilizing these proteins in predictive mathematical models may enable the development of risk stratification tools applicable in high-performance clinical settings.

Many of the identified proteomic biomarkers of obesity have also been reported to be dysregulated in obesity-related disease, such as T2DM, MAFLD, CVD and metabolic syndrome, among others (Fig. 5). Seven proteins have been reported to be altered in the four selected obesity comorbidities. These proteins belong to metabolic pathways (aldehyde dehydrogenase X and apolipoprotein A1), the chaperone family (albumin, heat shock protein beta 1, protein disulfide-isomerase A3), and oxidative stress and inflammation proteins (catalase and complement C3). These proteins could potentially serve as biomarkers for the progression of obesity and the development of comorbidities, thereby contributing to personalized medicine within the field of obesity. In proteomics, relying on a single biomarker may not provide a complete understanding of the complexity of the picture. Furthermore, certain biomarkers consistently appear, indicating a significant potential beyond their individual roles



Protein	Function	T2DM	CVD	MAFLD	MS	References
Albumin	Chaperone binding	x	x	x	x	[166], [167], [168], [169]
Heat shock protein beta-1	Chaperone binding	x	x	x	x	[170], [171], [172], [173]
Protein disulfide-isomerase A3	Chaperone binding	x	x	x	x	[81], [80], [174], [175]
Catalase	Inflammation and oxidative stress	x	x	x	x	[176], [177], [178], [179], [180]
Complement C3	Inflammation and oxidative stress	x	x	x	x	[181], [182], [129], [183]
Aldehyde dehydrogenase	Metabolic pathways	x	x	x	x	[184], [24], [185], [186]
Apolipoprotein A-I	Metabolic pathways	x	x	x	x	[187], [188], [189], [190]
Fibrinogen gamma chain	Coagulation cascades	x	x	x		[191], [93], [192], [193]
Hemoglobin subunit beta	Coagulation cascades	x	x	x		[99], [194], [195], [196]
Alpha enolase	Metabolic pathways	x	x	x		[197], [29], [198]
Actin	Structural constituent of cytoskeleton	x	x	x		[184], [199]
Galectin-1	Inflammation and oxidative stress	x	x		x	[200], [133]
Parkinson disease protein- 7	Inflammation and oxidative stress	x	x		x	[201], [202], [203]
Tropomyosin alpha-1 chain	Structural constituent of cytoskeleton	x	x		x	[114], [204], [115], [205]
Crystallin B chain, alpha	Chaperone binding	x	x			[184], [206], [207], [208]
Coagulation factor V	Coagulation cascades	x	x			[91], [209], [90], [210]
Fibrinogen beta chain	Coagulation cascades	x	x			[211], [212], [93], [213]
Integrin alpha-IIb	Coagulation cascades	x	x			[214], [215], [216]
Dihydropolyllysine residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial	Metabolic pathways	x	x			[217], [218]
Desmin	Structural constituent of cytoskeleton	x	x			[106], [56]
Glutathione-S-transferase P	Inflammation and oxidative stress	x		x	x	[219], [220], [221], [222], [223]
Mitochondrial pyruvate carrier- 1	Metabolic pathways	x		x		[224]
Lysozyme C	Inflammation and oxidative stress	x			x	[225], [121]
ATP synthase subunit beta	Metabolic pathways	x			x	[40], [38], [226], [227], [38]
Pyruvate kinase	Metabolic pathways	x			x	[228]
Creatine Kinase B- type	Metabolic pathways	x				[229]
Glyceraldehyde-3-phosphate dehydrogenase	Metabolic pathways	x				[51], [52], [254], [50], [230]
Phosphatidylinositol 5 phosphate 4 kinase type 2 alpha	Metabolic pathways	x				[231]
Gamma-synuclein	Structural constituent of cytoskeleton	x				[232]
Vimentin	Structural constituent of cytoskeleton	x				[117]
Apolipoprotein B-100	Metabolic pathways		x	x	x	[187], [233], [234], [235]
Annexin A5	Coagulation cascades		x	x		[260], [85], [88], [236]
Hemoglobin subunit alpha	Coagulation cascades		x			[99], [237], [194]
Amyloid P-component, serum	Inflammation and oxidative stress		x			[238], [124], [239]
Endoplasmic reticulum chaperone BiP	Chaperone binding			x	x	[240], [241], [242], [243]
Heat shock protein beta-1	Metabolic pathways	x		x	x	[20], [244]

Fig. 5 Relevant obesity proteomics biomarkers associated with obesity-related diseases. Colour-code represent their molecular function chaperon binding (green), coagulation cascades (light blue inflammation and oxidative stress (orange), metabolic pathways (red)) and structural constituent of cytoskeleton (yellow)

and pointing to common pathways of metabolic dysfunction response. Developing comprehensive panels for analysing the progression of obesity and enabling early detection of its comorbidities is becoming increasingly crucial in biomedical research.

Our analysis has revealed substantial variations in protein profiles across various human samples, spotlighting how obesity impacts tissue function at the molecular level. Higher number of altered proteins were found in AT and blood (platelets, plasma or EVs) from patients with obesity and those proteins were involved in the 6 reported biological processes. In obesity, the most relevant tissue is the AT as obesity is the result of AT expansion. Moreover, adipose tissue becomes dysfunctional in obesity and compromise global metabolic and health homeostasis. Blood, the circulatory system, transport not only nutrients and by-products of cells but also transport mediators of intercellular communication. Therefore, both tissues are relevant in obesity and proteins found on them can be important to understand obesity pathology and can represent new treatment avenues.

The application of proteomics techniques in the study of obesity has limitations and presents significant challenges. Current challenges include the multifactorial pathophysiology of obesity, the standardisation operating conditions and procedures, the sample selection and sample size, the heterogeneity of the proteins detected based on protocols/platforms, the need for computational tools to assess the biological significance of detected proteins, the validation of proteomic findings and the translation of experimental data to clinical practice.

Obesity is influenced by genetic predispositions, environmental factors and lifestyle choices, making it challenging to attribute to specific proteins. Additionally, proteomic studies face challenges related to the type of sample and processing, the invasive nature of obtaining tissue samples and the limited availability of tissue specimens. Moreover, limitations in current proteomic technologies include the inability to detect proteins of very low abundance and quantify small-fold changes in abundance accurately. Different experimental platforms are used in proteomics, each with advantages and limitations. No single method can detect and identify the whole proteome, so different techniques should be seen as complementary, not exclusive. Bioinformatics plays a critical role in interpreting proteomic results, utilizing various techniques for managing, analysing and interpreting large datasets. Of note, only when submitted to appropriate bioinformatics tools, proteomic results serve to approach and

solve biological problems. Finally, proteomics studies were limited by the possibility of a selection bias derived from the recruitment of both patients and controls in clinical-based population and by their relatively small sample sizes. Overcoming current limitations and advancing our understanding of obesity pathophysiology requires standardisation efforts, technological advancements and integration with other omics approaches. While we have made diligent efforts to account for these limitations, they remain potential sources of bias within the analysis. Therefore, future studies would benefit from standardized reporting and improved data sharing practices. Current standardisation efforts, such as the Human Proteome Organization (HUPO) Proteomics Initiative (PSI), aim to facilitate data comparison, exchange and verification of proteomics data. The development of more effective tools for data analysis and interpretation, and the improvements in the sensitivity of mass spectrometry instrumentation can help overcome the limitations and advance our understanding of obesity pathophysiology.

This systematic proteomics review presents several strengths that contribute to its significance in the field of obesity and associated metabolic diseases. First, the comprehensive nature of our analysis, selecting those altered proteins that were reported in at least 2 studies, encompassing a multitude of proteomic studies, allows us to draw conclusions about protein profiles across diverse human biological samples. This data integration enhances the robustness of our findings and provides a holistic perspective on the intricate interplay between proteins and the pathophysiology of obesity. Additionally, our incorporation of enrichment analyses reinforces the underlying molecular processes and metabolic pathways associated with obesity, further enriching our comprehension of the subject.

Proteomics offers a comprehensive overview of variations in protein abundance. One of the proteome's strengths lies in its dynamic responsiveness to environmental stimuli, including dietary factors and chemical exposures. Moreover, due to translational processes and post-translational modifications, direct correlation with the transcriptome is not always observed. Therefore, proteomic approaches are one layer of omics information and must be complemented and integrated with data obtained from genomics, epigenomics, transcriptomics, metabolomics and metagenomics approaches, to unravel the complex molecular and cellular modifications resulting in obesity. Obesity is driven by a combination of an underlying genetic predisposition, and environmental factors. Genomics identifies genetic variations that may be associated with diseases and prognosis, while epigenomics studies the heritable changes and chemical modifications that occur in our DNA. Transcriptomics examines messenger RNAs (mRNAs) and non-coding RNA (ncRNAs) to understand gene expression, while metabolomics studies the small molecules involved in metabolic pathways to understand the

biochemical processes. Human metagenomics examines the complete set of genes and genomes of the microbiota (bacteria, archaea, eukaryotes, and viruses) that reside in and on a person. Integrating multi-omics approaches in data analysis provides a more comprehensive view of molecular pathways underlying the development of obesity and comorbidities. It can lead to a significant shift from a generalized approach to a precise obesity management strategy. This includes precise prevention methods for obesity onset, tailored medicine for treating obesity, and targeted risk reduction strategies for preventing secondary diseases associated with obesity.

After the extensive research conducted in the proteomics analysis of individuals with obesity, the research faces a significant challenge in verifying the role of the identified proteins proposed in this systematic review. These proteins are being considered as potential indicators predicting susceptibility to obesity or its associated complications. Addressing this substantial challenge will require large cohorts comprising healthy and/or individuals with obesity to evaluate the significance of these proteins as biomarkers—a task not without considerable complexity.

The extensive research conducted in the proteomics analysis of individuals with obesity have shown proteins with significant potential as indicators for predicting susceptibility to obesity or its associated complications, enabling early detection screening, patient stratification, progression monitoring and identification of novel pharmaceutical targets for obesity and related diseases. Nevertheless, as the studies analysed in the present meta-analysis are cross-sectional, the research faces a significant challenge in verifying the causality and the role of the identified proteins proposed in this systematic review. Addressing this substantial challenge will require large prospective cohort studies comprising healthy and/or individuals with obesity to evaluate the significance of these proteins as biomarkers—a task not without considerable complexity. Therefore, future studies could focus on the evaluation of these proteins in subjects without obesity and observe if those with altered proteins are more prone to become obese. Similarly, a biomarker that elucidates the potential complications in patients with obesity, such as cardiovascular or hepatic diseases, is also of interest. To verify this, a cohort of individuals with obesity could be selected, examining those with additional complications and assessing whether these are associated with specific proteins. This could serve as a biomarker for obesity-related complications, some of which are challenging to diagnose early, like atherosclerosis before a heart attack or stroke. Alternatively, examining individuals with obesity without existing complications and monitoring the development of complications could provide insights into whether these proteins function as predictive biomarkers for obesity-related diseases. In addition, monitoring these identified proteins after obesity treatment, whether through surgery

or nutritional pharmaceutical interventions, could provide physicians with real time functional insights regarding the efficacy of the administered treatments.

In conclusion, our systematic proteomics review represents a substantial step forward in unravelling the complexities of obesity-related protein changes, offering valuable insights into the pathophysiological mechanisms, unlocking potential avenues for biomarker discovery and personalized medicine. Several proteomic biomarkers of obesity involved in metabolic pathways, the chaperone family and oxidative stress and inflammation proteins have also been reported to be dysregulated in obesity-related disease, which could potentially serve as biomarkers for the progression of obesity and the development of comorbidities, contributing to personalized medicine in the field of obesity. However, it is crucial to emphasize the need for validation studies in larger patient cohorts to enhance the robustness of these findings to build a stronger basis for this research in obesity.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s13679-024-00561-4>.

Acknowledgements J.R-C is supported by a postdoctoral contract from Consejería de Salud de la Junta de Andalucía, Spain (RH-0095-2020) and by Instituto de Salud Carlos III (ISCIII) through the project PI22/01833. M.M. is supported by Miguel Servet II program (CPII22-00013) and by the project “PI19/00507”, “PI23/00293” by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. M.M. is also supported by UMA18-FEDERJA-285 co-funded by Malaga University, Junta de Andalucía and FEDER funds, CB06/03/0018 and PI-0297-2018 co-funded by FEDER funds and Consejería de Salud y Familia, Junta de Andalucía, Spain. We have used several icons for Fig. 5 from www.freepik.com and in Fig. 4 from <https://thenounproject.com/>.

Author Contributions M.M and M.I contributed to the study conception and design and data collection and analysis. A.R-M and M.M wrote the draft of the article. A.R-M, H.M-R and L.M-C contributed to data collection and analysis. A.G-J contributed to the bioinformatic analysis. J.B-P, J. R-C and F.J.T analysed the data and revised the article critically for important intellectual content. A.R-M wrote the final version of the manuscript. All authors approved the final version of the article and take full responsibility for the accuracy of its content.

Funding Consejería de Salud y Consumo, Junta de Andalucía, RH-0095-2020, Instituto de Salud Carlos III, CPII22-00013, Universidad de Málaga, Andalucía, Spain, UMA18-FEDERJA-285, CB06/03/0018, PI-0297-2018

Data Availability No datasets were generated or analysed during the current study.

Declarations

Competing Interests The authors declare no competing interests.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Phelps NH, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. *The Lancet*. 2024. [https://doi.org/10.1016/S01406736\(23\)02750-2](https://doi.org/10.1016/S01406736(23)02750-2).
- Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. *Nat Rev Genet*. 2022;23(2):120–33. <https://doi.org/10.1038/s41576-021-00414-z>.
- Chong B, et al. Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019. *EClinicalMedicine*. 2023. <https://doi.org/10.1016/j.eclinm.2023.101850>.
- Goossens GH, Blaak EE. Adipose tissue dysfunction and impaired metabolic health in human obesity: a matter of oxygen? *Front Endocrinol (Lausanne)*. 2015;6:55. <https://doi.org/10.3389/fendo.2015.00055>.
- Portincasa P, Frühbeck G. Phenotyping the obesities: reality or utopia? *Rev Endocr Metab Disord*. 2023;24(5):767–73. <https://doi.org/10.1007/s11154-023-09829-x>.
- Darci-Maher N, et al. Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease. *EBioMedicine*. 2023. <https://doi.org/10.1016/j.ebiom.2023.104620>.
- Aleksandrova K, Egea Rodrigues C, Floegel A, Ahrens W. Omics biomarkers in obesity: novel etiological insights and targets for precision prevention. *Curr Obes Rep*. 2020;9(3):219–30. <https://doi.org/10.1007/s13679-020-00393-y>.
- Chen HC, et al. Parapharyngeal fat pad area at the subglossosupraglottic level is associated with corresponding lateral wall collapse and apnea-hypopnea index in patients with obstructive sleep apnea: a pilot study. *Sci Rep*. 2019;9(1):17722. <https://doi.org/10.1038/s41598-019-53515-5>.
- Al-Makhamreh HK, Toubasi AA, Al-Harasis LM, Albustanji FH, Al-Sayegh TN, Al-Harasis SM. Pericardial fat and cardiovascular diseases: a systematic review and meta-analysis. *J Evid Based Med*. 2023;16(2):178–85. <https://doi.org/10.1111/jebm.12542>.
- Santi D, et al. Does an increase in adipose tissue ‘weight’ affect male fertility? A systematic review and meta-analysis based on semen analysis performed using the WHO 2010 criteria. *Andrology*. 2023. <https://doi.org/10.1111/andr.13460>.
- Choi H, et al. Plasma protein and microRNA biomarkers of insulin resistance: a network-based integrative -omics analysis. *Front Physiol*. 2019. <https://doi.org/10.3389/fphys.2019.00379>.
- Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *PLoS Med*. 2021;18(3):e1003583. <https://doi.org/10.1371/journal.pmed.1003583>.
- Chandramouli K, Qian PY. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. *Hum Genomics Proteomics*. 2009. <https://doi.org/10.4061/2009/239204>.
- Oberbach A, et al. Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. *J Proteome Res*. 2011;10(10):4769–88. <https://doi.org/10.1021/pr2005555>.
- Karlsson H, Mörstedt H, Lindqvist H, Tagesson C, Lindahl M. Protein profiling of low-density lipoprotein from obese subjects. *Proteomics Clin Appl*. 2009;3(6):663–71. <https://doi.org/10.1002/prca.200800138>.
- Brown KA. Metabolic pathways in obesity-related breast cancer. *Nat Rev Endocrinol*. 2021;17(6):350–63. <https://doi.org/10.1038/s41574-021-00487-0>.
- Li Y-J, Zhang C, Martincuks A, Herrmann A, Yu H. STAT proteins in cancer: orchestration of metabolism. *Nat Rev Cancer*. 2023;23(3):115–34. <https://doi.org/10.1038/s41568-022-00537-3>.
- Jelski W, Sani TA, Szmikowski M. Class III alcohol dehydrogenase and its role in the human body. *Postepy Hig Med Dosw (Online)*. 2006;60:406–9.
- Sebag SC, et al. ADH5-mediated NO bioactivity maintains metabolic homeostasis in brown adipose tissue. *Cell Rep*. 2021;37(7):110003. <https://doi.org/10.1016/j.celrep.2021.110003>.
- Moody L, Shao J, Chen H, Pan Y-X. Maternal low-fat diet programs the hepatic epigenome despite exposure to an obesogenic postnatal diet. *Nutrients*. 2019. <https://doi.org/10.3390/nu1092075>.
- Pini T, et al. Obesity significantly alters the human sperm proteome, with potential implications for fertility. *J Assist Reprod Genet*. 2020;37(4):777–87. <https://doi.org/10.1007/s10815-020-01707-8>.
- Grande R, et al. Platelet-derived microparticles from obese individuals: characterization of number, size, proteomics, and crosstalk with cancer and endothelial cells. *Front Pharmacol*. 2019;10:7. <https://doi.org/10.3389/fphar.2019.00007>.
- Hu C. Aldehyde dehydrogenases genetic polymorphism and obesity: from genomics to behavior and health. *Adv Exp Med Biol*. 2019;1193:135–54. https://doi.org/10.1007/978-981-13-6260-6_8.
- Boden G, et al. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. *Diabetes*. 2008;57(9):2438–44. <https://doi.org/10.2337/db08-0604>.
- Benabdelkamel H, et al. Mature adipocyte proteome reveals differentially altered protein abundances between lean, overweight and morbidly obese human subjects. *Mol Cell Endocrinol*. 2015;401:142–54. <https://doi.org/10.1016/j.mce.2014.11.021>.
- Kras KA, et al. Obesity modifies the stoichiometry of mitochondrial proteins in a way that is distinct to the subcellular localization of the mitochondria in skeletal muscle. *Metabolism*. 2018;89:18–26. <https://doi.org/10.1016/j.metabol.2018.09.006>.
- Abdul-Ghani MA, Jani R, Chavez A, Molina-Carrion M, Tripathy D, Defronzo RA. Mitochondrial reactive oxygen species generation in obese non-diabetic and type 2 diabetic participants. *Diabetologia*. 2009;52(4):574–82. <https://doi.org/10.1007/s00125-009-1264-4>.
- Berggren JR, Boyle KE, Chapman WH, Houmar JA. Skeletal muscle lipid oxidation and obesity: influence of weight loss and exercise. *Am J Physiol Endocrinol Metab*. 2008;294(4):E726–32. <https://doi.org/10.1152/ajpendo.00354.2007>.
- Cho H, et al. ENOblock inhibits the pathology of diet-induced obesity. *Sci Rep*. 2019;9(1):493. <https://doi.org/10.1038/s41598-018-36715-3>.
- Qiao Q, et al. Adipocyte abundances of CES1, CRYAB, ENO1 and GANAB are modified in-vitro by glucose restriction and are

- associated with cellular remodelling during weight regain. *Adipocyte*. 2019;8(1):190–200. <https://doi.org/10.1080/21623945.2019.1608757>.
31. Soedarman S, Julia M, Gondhowiardjo TD, Prasetya ADB, Kurnia KH, Sasongko MB. Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetes. *BMJ Open Ophthalmol*. 2023. <https://doi.org/10.1136/bmjophth-2022-001207>.
 32. Azmi S, et al. The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity. *Sci Rep*. 2021;11(1):12573. <https://doi.org/10.1038/s41598-021-90346-9>.
 33. Sant'Anna VAR, Izar MCO, Gidlund M, Fonseca HAR, Vaccine Heart Group. Autoantibodies against an immunodominant epitope from apolipoprotein B and risk of cardiovascular events in subjects with type 2 diabetes. *Eur J Intern Med*. 2023. <https://doi.org/10.1016/j.ejim.2023.07.018>.
 34. Zhang C, Ni J, Chen Z. Apolipoprotein B displays superior predictive value than other lipids for long-term prognosis in coronary atherosclerosis patients and particular subpopulations: a retrospective study. *Clin Ther*. 2022;44(8):1071–92. <https://doi.org/10.1016/j.clinthera.2022.06.010>.
 35. Ho JH, et al. Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a). *J Clin Lipidol*. 2021;15(2):320–31. <https://doi.org/10.1016/j.jacl.2020.12.002>.
 36. Shang C, et al. Comparative proteomic analysis of visceral adipose tissue in morbidly obese and normal weight chinese women. *Int J Endocrinol*. 2019;2019:2302753. <https://doi.org/10.1155/2019/2302753>.
 37. Chen CC, et al. Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model. *Proteomics*. 2017;17:1–2. <https://doi.org/10.1002/prot.201600292>.
 38. Formentini L, et al. Mitochondrial H⁺-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. *Diabetologia*. 2017;60(10):2052–65. <https://doi.org/10.1007/s00125-017-4379-z>.
 39. Tran L, et al. Prolonged exposure of primary human muscle cells to plasma fatty acids associated with obese phenotype induces persistent suppression of muscle mitochondrial ATP synthase β subunit. *PLoS One*. 2016;11(8):e0160057. <https://doi.org/10.1371/journal.pone.0160057>.
 40. Højlund K, et al. Human ATP synthase beta is phosphorylated at multiple sites and shows abnormal phosphorylation at specific sites in insulin-resistant muscle. *Diabetologia*. 2010;53(3):541–51. <https://doi.org/10.1007/s00125-009-1624-0>.
 41. Rahbani JF, et al. Creatine kinase B controls futile creatine cycling in thermogenic fat. *Nature*. 2021;590(7846):480–5. <https://doi.org/10.1038/s41586-021-03221-y>.
 42. Saad B. A review of the anti-obesity effects of wild edible plants in the Mediterranean diet and their active compounds: from traditional uses to action mechanisms and therapeutic targets. *Int J Mol Sci*. 2023;24:16. <https://doi.org/10.3390/ijms241612641>.
 43. Shang C, et al. Comparative proteomic analysis of visceral adipose tissue in morbidly obese and normal weight chinese women. *Int J Endocrinol*. 2019. <https://doi.org/10.1155/2019/2302753>.
 44. Remacha L, et al. Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas. *Am J Hum Genet*. 2019;104(4):651–64. <https://doi.org/10.1016/j.ajhg.2019.02.017>.
 45. Tajima K, et al. Mitochondrial lipoylation integrates age-associated decline in brown fat thermogenesis. *Nat Metab*. 2019;1(9):886–98. <https://doi.org/10.1038/s42255-019-0106-z>.
 46. Barrachina MN, et al. A combination of proteomic approaches identifies a panel of circulating extracellular vesicle proteins related to the risk of suffering cardiovascular disease in obese patients. *Proteomics*. 2019;19(1–2):e1800248. <https://doi.org/10.1002/prot.201800248>.
 47. Flick MJ, Konieczny SF. Identification of putative mammalian D-lactate dehydrogenase enzymes. *Biochem Biophys Res Commun*. 2002;295(4):910–6. [https://doi.org/10.1016/s0006-291x\(02\)00768-4](https://doi.org/10.1016/s0006-291x(02)00768-4).
 48. Chou C-K, et al. Elevated urinary D-lactate levels in patients with diabetes and microalbuminuria. *J Pharm Biomed Anal*. 2015;116:65–70. <https://doi.org/10.1016/j.jpba.2015.06.014>.
 49. Brant Pinheiro SV, et al. Acute post-streptococcal glomerulonephritis in children: a comprehensive review. *Curr Med Chem*. 2022;29(34):5543–59. <https://doi.org/10.2174/0929867329666220613103316>.
 50. Sartor F, et al. Adaptive metabolic response to 4 weeks of sugar-sweetened beverage consumption in healthy, lightly active individuals and chronic high glucose availability in primary human myotubes. *Eur J Nutr*. 2013;52(3):937–48. <https://doi.org/10.1007/s00394-012-0401-x>.
 51. Hittel DS, Hathout Y, Hoffman EP, Houmard JA. Proteome analysis of skeletal muscle from obese and morbidly obese women. *Diabetes*. 2005;54(5):1283–8. <https://doi.org/10.2337/diabetes.54.5.1283>.
 52. Giebelstein J, et al. The proteomic signature of insulin-resistant human skeletal muscle reveals increased glycolytic and decreased mitochondrial enzymes. *Diabetologia*. 2012;55(4):1114–27. <https://doi.org/10.1007/s00125-012-2456-x>.
 53. Yang H, Du L, Zhang Z. Potential biomarkers in septic shock besides lactate. *Exp Biol Med (Maywood)*. 2020;245(12):1066–72. <https://doi.org/10.1177/1535370220919076>.
 54. Kim EY, et al. Acetylation of malate dehydrogenase 1 promotes adipogenic differentiation via activating its enzymatic activity. *J Lipid Res*. 2012;53(9):1864–76. <https://doi.org/10.1194/jlr.M026567>.
 55. Grande R, et al. Platelet-derived microparticles from obese individuals: Characterization of number, size, proteomics, and crosstalk with cancer and endothelial cells. *Front Pharmacol*. 2019. <https://doi.org/10.3389/fphar.2019.00007>.
 56. Coletta DK, Mandarino LJ. Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria. *Am J Physiol Endocrinol Metab*. 2011;301(5):E749–55. <https://doi.org/10.1152/ajpendo.00363.2011>.
 57. Gao R, et al. Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease. *Hepatology*. 2023. <https://doi.org/10.1097/HEP.000000000000279>.
 58. Liu Y, et al. Mitochondrial pyruvate carrier 1 alleviates hypoxic-ischemic brain injury in rats. *Life Sci*. 2023;325: 121686. <https://doi.org/10.1016/j.lfs.2023.121686>.
 59. Hu A, et al. PIP4K2A regulates intracellular cholesterol transport through modulating PI(4,5)P2 homeostasis. *J Lipid Res*. 2018;59(3):507–14. <https://doi.org/10.1194/jlr.M082149>.
 60. Duan H, Song P, Li R, Su H, He L. Attenuating lipid metabolism in atherosclerosis: the potential role of Anti-oxidative effects on low-density lipoprotein of herbal medicines. *Front Pharmacol*. 2023;14:1161657. <https://doi.org/10.3389/fphar.2023.1161657>.
 61. Freedman J. Platelets, obesity, and the metabolic syndrome. *Blood*. 2011;118(21):34. <https://doi.org/10.1182/blood.V118.21.SCI-34.SCI-34>.
 62. Zhu Q, et al. LncRNA HClnc1 facilitates hepatocellular carcinoma progression by regulating PKM2 signaling and indicates poor survival outcome after hepatectomy. *Cancer Med*. 2023;12(13):14526–44. <https://doi.org/10.1002/cam4.6117>.
 63. Moreno-Fernandez ME, et al. PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease. *Cell Metab*. 2021;33(6):1187–1204.e9. <https://doi.org/10.1016/j.cmet.2021.04.018>.

64. Binder MJ, Pedley AM. The roles of molecular chaperones in regulating cell metabolism. *FEBS Lett.* 2023;597(13):1681–701. <https://doi.org/10.1002/1873-3468.14682>.
65. Ajoobabady A, et al. ER stress in obesity pathogenesis and management. *Trends Pharmacol Sci.* 2022;43(2):97–109. <https://doi.org/10.1016/j.tips.2021.11.011>.
66. Engin F, Hotamisligil GS. Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases. *Diabetes Obes Metab.* 2010;12(s2):108–15. <https://doi.org/10.1111/j.1463-1326.2010.01282.x>.
67. Jun JE, et al. Increase in serum albumin concentration is associated with prediabetes development and progression to overt diabetes independently of metabolic syndrome. *PLoS One.* 2017;12(4):e0176209. <https://doi.org/10.1371/journal.pone.0176209>.
68. Mosli RH, Mosli HH. Obesity and morbid obesity associated with higher odds of hypoalbuminemia in adults without liver disease or renal failure. *Diabetes Metab Syndr Obes.* 2017;10:467–72. <https://doi.org/10.2147/DMSO.S149832>.
69. Dimauro I, Caporossi D. Alpha B-crystallin in muscle disease prevention: the role of physical activity. *Molecules.* 2022. <https://doi.org/10.3390/molecules27031147>.
70. Fu L, Liang JJ-N. Enhanced stability of alpha B-crystallin in the presence of small heat shock protein Hsp27. *Biochem Biophys Res Commun.* 2003;302(4):710–4. [https://doi.org/10.1016/s0006-291x\(03\)00257-2](https://doi.org/10.1016/s0006-291x(03)00257-2).
71. Wang J, Lee J, Liem D, Ping P. HSPA5 gene encoding Hsp70 chaperone BiP in the endoplasmic reticulum. *Gene.* 2017;618:14–23. <https://doi.org/10.1016/j.gene.2017.03.005>.
72. Shin J, et al. Possible involvement of adipose tissue in patients with older age, obesity, and diabetes with SARS-CoV-2 infection (COVID-19) via GRP78 (BIP/HSPA5): significance of hyperinsulinemia management in COVID-19. *Diabetes.* 2021;70(12):2745–55. <https://doi.org/10.2337/db20-1094>.
73. Hazra J, Vijayakumar A, Mahapatra NR. Emerging role of heat shock proteins in cardiovascular diseases. *Adv Protein Chem Struct Biol.* 2023;134:271–306. <https://doi.org/10.1016/bs.apcsb.2022.10.008>.
74. Jing X-Y, Li F-M. Identifying heat shock protein families from imbalanced data by using combined features. *Comput Math Methods Med.* 2020;2020:8894478. <https://doi.org/10.1155/2020/8894478>.
75. Pilch W, et al. The effect of whole-body cryostimulation on body composition and leukocyte expression of HSPA1A, HSPB1, and CRP in obese men. *Cryobiology.* 2020;94:100–6. <https://doi.org/10.1016/j.cryobiol.2020.04.002>.
76. Li F, Xiao H, Zhou F, Hu Z, Yang B. Study of HSPB6: insights into the properties of the multifunctional protective agent. *Cell Physiol Biochem.* 2017;44(1):314–32. <https://doi.org/10.1159/000484889>.
77. DeLany JP, et al. Proteomic analysis of primary cultures of human adipose-derived stem cells. *Mol Cell Proteomics.* 2005;4(6):731–40. <https://doi.org/10.1074/mcp.M400198-MCP200>.
78. Peng J, et al. An Hsp20-FBXO4 Axis regulates adipocyte function through modulating PPAR γ ubiquitination. *Cell Rep.* 2018;23(12):3607–20. <https://doi.org/10.1016/j.celrep.2018.05.065>.
79. Kondo R, et al. Downregulation of protein disulfide-isomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling in hepatocellular carcinoma. *Int J Oncol.* 2019. <https://doi.org/10.3892/ijo.2019.4710>.
80. Antoniotti V, et al. Calreticulin and PDIA3, two markers of endoplasmic reticulum stress, are associated with metabolic alterations and insulin resistance in pediatric obesity: A pilot study. *Front Endocrinol (Lausanne).* 2022;13:1003919. <https://doi.org/10.3389/fendo.2022.1003919>.
81. Boden G, Merali S. Measurement of the increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. *Methods Enzymol.* 2011;489:67–82. <https://doi.org/10.1016/B978-0-12-385116-1.00004-2>.
82. Vilahur G, Ben-Aicha S, Badimon L. New insights into the role of adipose tissue in thrombosis. *Cardiovasc Res.* 2017;113(9):1046–54. <https://doi.org/10.1093/cvr/cvx086>.
83. Noris M, Galbusera M. The complement alternative pathway and hemostasis. *Immunol Rev.* 2023;313(1):139–61. <https://doi.org/10.1111/imr.13150>.
84. Shim K, Begum R, Yang C, Wang H. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. *World J Diabetes.* 2020;11(1):1–12. <https://doi.org/10.4239/wjcd.v11.i1.1>.
85. Oliva K, et al. The effect of pre-existing maternal obesity on the placental proteome: two-dimensional difference gel electrophoresis coupled with mass spectrometry. *J Mol Endocrinol.* 2012;48(2):139–49. <https://doi.org/10.1530/JME-11-0123>.
86. Dennis M, Downey C, Brufatto N, Nesheim M, Stevenson K, Toh C. Prothrombinase enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein. *Thromb Haemost.* 2004;91(03):522–30. <https://doi.org/10.1160/TH03-08-0548>.
87. Grewal T, Enrich C, Rentero C, Buechler C. Annexins in adipose tissue: novel players in obesity. *Int J Mol Sci.* 2019;20(14):3449. <https://doi.org/10.3390/ijms20143449>.
88. Seok H, et al. Association of annexin A5 polymorphisms with obesity. *Biomed Rep.* 2013;1(4):654–8. <https://doi.org/10.3892/br.2013.118>.
89. Batsuli G, Kouides P. Rare coagulation factor deficiencies (factors VII, X, V, and II). *Hematol Oncol Clin North Am.* 2021;35(6):1181–96. <https://doi.org/10.1016/j.hoc.2021.07.010>.
90. De Pablo-Moreno JA, Miguel-Batuecas A, de Sancha M, Liras A. The magic of proteases: from a procoagulant and anticoagulant factor V to an equitable treatment of its inherited deficiency. *Int J Mol Sci.* 2023. <https://doi.org/10.3390/ijms24076243>.
91. Kornblith LZ, et al. Obesity and clotting: body mass index independently contributes to hypercoagulability after injury. *J Trauma Acute Care Surg.* 78(1):30–6; discussion 37–8, Jan. 2015. <https://doi.org/10.1097/TA.0000000000000490>.
92. Jabber HA, Alsaidissa JN, Al-Rubaie HA. The relationship between obesity and plasma level of factor V and fibrinogen. *Journal of the Faculty of Medicine-Baghdad.* 2017;59(1):53–9. <https://doi.org/10.32007/med.1936/jfacmedbagdad.v59i1.11>.
93. Mossesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. *Ann N Y Acad Sci.* 2001;936:11–30. <https://doi.org/10.1111/j.1749-6632.2001.tb03491.x>.
94. Lovely R, et al. Obesity-related increased γ fibrinogen concentration in children and its reduction by a physical activity-based lifestyle intervention: a randomized controlled study. *J Pediatr.* 2013;163(2):333–8. <https://doi.org/10.1016/j.jpeds.2013.01.004>.
95. Barrachina MN, et al. Data on hyper-activation of GPVI signaling in obese patients: Towards the identification of novel anti-platelet targets in obesity. *Data Brief.* 2019;23: 103784. <https://doi.org/10.1016/j.dib.2019.103784>.
96. Andrade S, Morais T, Sandovici I, Seabra AL, Constância M, Monteiro MP. Adipose tissue epigenetic profile in obesity-related dysglycemia—a systematic review. *Front Endocrinol (Lausanne).* 2021;12:681649. <https://doi.org/10.3389/fendo.2021.681649>.
97. Kamruzzaman M. Is BMI associated with anemia and hemoglobin level of women and children in Bangladesh: A study with multiple statistical approaches. *PLoS ONE.* 2021;16(10):e0259116. <https://doi.org/10.1371/journal.pone.0259116>.
98. Ghadiri-Anari A, Nazemian N, Vahedian-Ardakani H-A. Association of body mass index with hemoglobin concentration

- and iron parameters in Iranian population. *ISRN Hematol.* 2014;2014:1–3. <https://doi.org/10.1155/2014/525312>.
99. Doumately AP, Zhou J, Zhou M, Prieto D, Rotimi CN, Adeyemo A. Proinflammatory and lipid biomarkers mediate metabolically healthy obesity: a proteomics study. *Obesity (Silver Spring)*. 2016;24(6):1257–65. <https://doi.org/10.1002/oby.21482>.
 100. Payrastra B, Missy K, Trumel C, Bodin S, Plantavid M, Chap H. The integrin alpha IIB/beta 3 in human platelet signal transduction. *Biochem Pharmacol.* 2000;60(8):1069–74. [https://doi.org/10.1016/s0006-2952\(00\)00417-2](https://doi.org/10.1016/s0006-2952(00)00417-2).
 101. Gibieža P, Petrikaitė V. The regulation of actin dynamics during cell division and malignancy. *Am J Cancer Res.* 2021;11(9):4050–69.
 102. Fan X, et al. High-fat diet alters the expression of reference genes in male mice. *Front Nutr.* 2020;7: 589771. <https://doi.org/10.3389/fnut.2020.589771>.
 103. Paulin D, Li Z. Desmin: a major intermediate filament protein essential for the structural integrity and function of muscle. *Exp Cell Res.* 2004;301(1):1–7. <https://doi.org/10.1016/j.yexcr.2004.08.004>.
 104. Elsnicova B, et al. Desmin knock-out cardiomyopathy: a heart on the verge of metabolic crisis. *Int J Mol Sci.* 2022;23(19):12020. <https://doi.org/10.3390/ijms231912020>.
 105. Cruz-Topete D, List EO, Okada S, Kelder B, Kopchick JJ. Proteomic changes in the heart of diet-induced pre-diabetic mice. *J Proteomics.* 2011;74(5):716–27. <https://doi.org/10.1016/j.jprot.2011.02.018>.
 106. Hwang H, et al. Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and type 2 diabetes. *Diabetes.* 2010;59(1):33–42. <https://doi.org/10.2337/db09-0214>.
 107. Oort PJ, et al. Gamma-synuclein is an adipocyte-neuron gene coordinately expressed with leptin and increased in human obesity. *J Nutr.* 2008;138(5):841–8. <https://doi.org/10.1093/jn/138.5.841>.
 108. Dunn TN, et al. Evaluation of the synuclein- γ (SNCG) gene as a PPAR γ target in murine adipocytes, dorsal root ganglia somatosensory neurons, and human adipose tissue. *PLoS One.* 2015;10(3):e0115830. <https://doi.org/10.1371/journal.pone.0115830>.
 109. Giuliani E, et al. Obesity-induced follicular phase endometrial proteome dysregulation in a well-phenotyped population. *F and S Science.* 2022;3(4):367–75. <https://doi.org/10.1016/j.xfss.2022.06.002>.
 110. Orfanos S, et al. Obesity increases airway smooth muscle responses to contractile agonists. *Am J Physiol Lung Cell Mol Physiol.* 2018;315(5):L673–81. <https://doi.org/10.1152/ajplung.00459.2017>.
 111. Prats-Puig A, et al. DNA methylation reorganization of skeletal muscle-specific genes in response to gestational obesity. *Front Physiol.* 2020;11:938. <https://doi.org/10.3389/fphys.2020.00938>.
 112. Zhu Z, et al. Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank. *J Allergy Clin Immunol.* 2020;145(2):537–49. <https://doi.org/10.1016/j.jaci.2019.09.035>.
 113. Kelly A, Chan J, Powell TL, Cox LA, Jansson T, Rosario FJ. Maternal obesity alters the placental transcriptome in a fetal sex-dependent manner. *Front Cell Dev Biol.* 2023;11:1178533. <https://doi.org/10.3389/fcell.2023.1178533>.
 114. Cai W, et al. Modulating lysine crotonylation in cardiomyocytes improves myocardial outcomes. *Circ Res.* 2022;131(5):456–72. <https://doi.org/10.1161/CIRCRESAHA.122.321054>.
 115. Sobue K, Hayashi K, Nishida W. Molecular mechanism of phenotypic modulation of smooth muscle cells. *Horm Res.* 1998;50(Suppl 2):15–24. <https://doi.org/10.1159/000053119>.
 116. Paulin D, Lilienbaum A, Kardjian S, Agbulut O, Li Z. Vimentin: regulation and pathogenesis. *Biochimie.* 2022;197:96–112. <https://doi.org/10.1016/j.biochi.2022.02.003>.
 117. Roh E, Yoo HJ. The role of adipose tissue lipolysis in diet-induced obesity: focus on vimentin. *Diabetes Metab J.* 2021;45(1):43–5. <https://doi.org/10.4093/dmj.2020.0293>.
 118. Shen W-J, Patel S, Eriksson JE, Kraemer FB. Vimentin is a functional partner of hormone sensitive lipase and facilitates lipolysis. *J Proteome Res.* 2010;9(4):1786–94. <https://doi.org/10.1021/pr900909t>.
 119. Wilhelmsson U, Stillemark-Billton P, Borén J, Pekny M. Vimentin is required for normal accumulation of body fat. *Biol Chem.* 2019;400(9):1157–62. <https://doi.org/10.1515/hsz-2019-0170>.
 120. Kim S, Kim I, Cho W, Oh GT, Park YM. Vimentin deficiency prevents high-fat diet-induced obesity and insulin resistance in mice. *Diabetes Metab J.* 2021;45(1):97–108. <https://doi.org/10.4093/dmj.2019.0198>.
 121. Moreno-Navarrete JM, et al. Lysozyme is a component of the innate immune system linked to obesity associated-chronic low-grade inflammation and altered glucose tolerance. *Clin Nutr.* 2021;40(3):1420–9. <https://doi.org/10.1016/j.clnu.2020.08.036>.
 122. Fernández-Sánchez A, et al. Inflammation, oxidative stress, and obesity. *Int J Mol Sci.* 2011;12(5):3117–32. <https://doi.org/10.3390/ijms12053117>.
 123. Cox N, Pilling D, Gomer RH. Serum amyloid P: a systemic regulator of the innate immune response. *J Leukoc Biol.* 2014;96(5):739–43. <https://doi.org/10.1189/jlb.1MR0114-068R>.
 124. Anwer M, Iqbal MJ. Serum amyloid p and endocrine markers in a cohort of obese children. *Indian J Endocrinol Metab.* 2018;22(5):683–8. https://doi.org/10.4103/ijem.IJEM_66_18.
 125. Pilling D, Cox N, Thomson MA, Karhadkar TR, Gomer RH. Serum amyloid P and a dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin ligand inhibit high-fat diet-induced adipose tissue and liver inflammation and steatosis in mice. *Am J Pathol.* 2019;189(12):2400–13. <https://doi.org/10.1016/j.ajpath.2019.08.005>.
 126. Murri M, et al. Changes in oxidative stress and insulin resistance in morbidly obese patients after bariatric surgery. *Obes Surg.* 2010;20(3):363–8. <https://doi.org/10.1007/s11695-009-0021-6>.
 127. Ahmed M, Neville MJ, Edelmann MJ, Kessler BM, Karpe F. Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. *Obesity (Silver Spring)*. 2010;18(1):27–34. <https://doi.org/10.1038/oby.2009.208>.
 128. Lipsa D, et al. Inter-individual variations: a challenge for the standardisation of complement activation assays. *Int J Nanomedicine.* 2023;18:711–20. <https://doi.org/10.2147/IJN.S384184>.
 129. Phielor J, Garcia-Martin R, Lambris JD, Chavakis T. The role of the complement system in metabolic organs and metabolic diseases. *Semin Immunol.* 2013;25(1):47–53. <https://doi.org/10.1016/j.smim.2013.04.003>.
 130. Nishimura T, et al. Clinical significance of serum complement factor 3 in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract.* 2017;127:132–9. <https://doi.org/10.1016/j.diabres.2017.03.017>.
 131. Cutine AM, et al. Tissue-specific control of galectin-1-driven circuits during inflammatory responses. *Glycobiology.* 2021;31(8):891–907. <https://doi.org/10.1093/glycob/cwab007>.
 132. Weigert J, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. *J Clin Endocrinol Metab.* 2010;95(3):1404–11. <https://doi.org/10.1210/jc.2009-1619>.
 133. Fryk E, Silva VRR, Jansson P-A. Galectin-1 in obesity and type 2 diabetes. *Metabolites.* 2022. <https://doi.org/10.3390/metabo12100930>.
 134. Sun Y, et al. A GSTP1-mediated lactic acid signaling promotes tumorigenesis through the PPP oxidative branch. *Cell Death Dis.* 2023;14(7):463. <https://doi.org/10.1038/s41419-023-05998-4>.

135. Zhang J, Grek C, Ye Z-W, Manevich Y, Tew KD, Townsend DM. Pleiotropic functions of glutathione S-transferase P. *Adv Cancer Res.* 2014;122:143–75. <https://doi.org/10.1016/B978-0-12-420117-0.00004-9>.
136. Mansour-Ghanaei F, Joukar F, Mobaraki SN, Mavaddati S, Hassani-pour S, Sepelrmanesh M. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: a cross-sectional study in north of Iran. *Diabetes Metab Syndr.* 2019;13(2):1591–6. <https://doi.org/10.1016/j.dsx.2019.03.009>.
137. Chielle EO, et al. Impact of the Ile105Val polymorphism of the glutathione S-transferase P1 (GSTP1) gene on obesity and markers of cardiometabolic risk in young adult population. *Exp Clin Endocrinol Diabetes.* 2017;125(5):335–41. <https://doi.org/10.1055/s-0042-105279>.
138. Xie D, et al. Effects of flavonoid supplementation on nanomaterial-induced toxicity: a meta-analysis of preclinical animal studies. *Front Nutr.* 2022;9: 929343. <https://doi.org/10.3389/fnut.2022.929343>.
139. Ragland SA, Criss KA. From bacterial killing to immune modulation: Recent insights into the functions of lysozyme. *PLoS Pathog.* 2017;13(9):463 <https://doi.org/10.1038/s41419-023-05998-4>
140. Hodin CM, et al. Reduced Paneth cell antimicrobial protein levels correlate with activation of the unfolded protein response in the gut of obese individuals. *J Pathol.* 2011;225(2):276–84. <https://doi.org/10.1002/path.2917>.
141. Kim J-M, et al. DJ-1 contributes to adipogenesis and obesity-induced inflammation. *Sci Rep.* 2014;4:4805. <https://doi.org/10.1038/srep04805>.
142. Silvester AJ, et al. Loss of DJ-1 promotes browning of white adipose tissue in diet-induced obese mice. *J Nutr Biochem.* 2018;61:56–67. <https://doi.org/10.1016/j.jnutbio.2018.07.004>.
143. Perez-Pérez R, et al. Differential proteomics of omental and subcutaneous adipose tissue reflects their unlike biochemical and metabolic properties. *J Proteome Res.* 2009;8(4):1682–93. <https://doi.org/10.1021/pr800942k>.
144. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. *Nat Biotechnol.* 2003;21(3):255–61. <https://doi.org/10.1038/nbt0303-255>.
145. Koliaki C, Dalamaga M, Liatis S. Update on the obesity epidemic: after the sudden rise, is the upward trajectory beginning to flatten? *Curr Obes Rep.* 2023. <https://doi.org/10.1007/s13679-023-00527-y>.
146. Roumans NJT, Vink RG, Bouwman FG, Fazelzadeh P, van Baak MA, Mariman ECM. Weight loss-induced cellular stress in subcutaneous adipose tissue and the risk for weight regain in overweight and obese adults. *Int J Obes (Lond).* 2017;41(6):894–901. <https://doi.org/10.1038/ijo.2016.221>.
147. Dong T. Activation of GPR3- β -arrestin2-PKM2 pathway in Kupffer cells stimulates glycolysis and inhibits obesity and liver pathogenesis. *Nat Commun.* 2024;15(1):807. <https://doi.org/10.1038/s41467-024-45167-5>.
148. Jonckheere AI, Smeitink JAM, Rodenburg RJT. Mitochondrial ATP synthase: architecture, function and pathology. *J Inher Metab Dis.* 2012;35(2):211–25. <https://doi.org/10.1007/s10545-011-9382-9>.
149. Lin Y-S, Cheng T-H, Chang C-P, Chen H-M, Chern Y. Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington’s disease. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.* 2013;1832(6):742–53. <https://doi.org/10.1016/j.bbadis.2013.02.006>.
150. Smith RL, Soeters MR, Wüst RCI, Houtkooper RH. Metabolic flexibility as an adaptation to energy resources and requirements in health and disease. *Endocr Rev.* 2018;39(4):489–517. <https://doi.org/10.1210/er.2017-00211>.
151. Zhang Y, et al. Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. *Cancers (Basel).* 2022;14(19):4568. <https://doi.org/10.3390/cancers14194568>.
152. Behbodikhah J, et al. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. *Metabolites.* 2021. <https://doi.org/10.3390/metabo11100690>.
153. Pietrocola F, Bravo-San Pedro JM. Targeting autophagy to counteract obesity-associated oxidative stress. *Antioxidants (Basel).* 2021. <https://doi.org/10.3390/antiox10010102>.
154. Khanna D, Khanna S, Khanna P, Kahar P, Patel BM. Obesity: a chronic low-grade inflammation and its markers. *Cureus.* 2022;14(2):e22711. <https://doi.org/10.7759/cureus.22711>.
155. Connaughton RM, McMorrow AM, McGillicuddy FC, Lithander FE, Roche HM. Impact of anti-inflammatory nutrients on obesity-associated metabolic-inflammation from childhood through to adulthood. *Proceedings of the Nutrition Society.* 2016;75(2):115–24. <https://doi.org/10.1017/S0029665116000070>.
156. Abdali D, Samson SE, Grover AK. How effective are antioxidant supplements in obesity and diabetes? *Med Princ Pract.* 2015;24(3):201–15. <https://doi.org/10.1159/000375305>.
157. Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. *Nat Rev Drug Discov.* 2021;20(9):689–709. <https://doi.org/10.1038/s41573-021-00233-1>.
158. Sharma R. Biochemical mechanisms of fatty liver and bioactive foods, in *Bioactive Food as Dietary Interventions for Liver and Gastrointestinal Disease.* Elsevier. 2013. <https://doi.org/10.1016/B978-0-12-397154-8.00181-0>.
159. René P, Lanfray D, Richard D, Bouvier M. Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity. *JCI Insight.* 2021. <https://doi.org/10.1172/jci.insight.132778>.
160. Shin J, et al. HSP47 levels determine the degree of body adiposity. *Nat Commun.* 2023;14(1):7319. <https://doi.org/10.1038/s41467-023-43080-x>.
161. Henstridge DC, Whitham M, Febbraio MA. Chaperoning to the metabolic party: The emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetes. *Mol Metab.* 2014;3(8):781–93. <https://doi.org/10.1016/j.molmet.2014.08.003>.
162. Santilli F, Vazzana N, Liani R, Guagnano MT, Davi G. Platelet activation in obesity and metabolic syndrome. *Obes Rev.* 2012;13(1):27–42. <https://doi.org/10.1111/j.1467-789X.2011.00930.x>.
163. Barale C, Melchionda E, Tempesta G, Morotti A, Russo I. Impact of physical exercise on platelets: focus on its effects in metabolic chronic diseases. *Antioxidants (Basel).* 2023. <https://doi.org/10.3390/antiox12081609>.
164. Bladbjerg EM, Stolberg CR, Juhl CB. Effects of obesity surgery on blood coagulation and fibrinolysis: a literature review. *Thromb Haemost.* 2020;120(4):579–91. <https://doi.org/10.1055/s-0040-1702224>.
165. Zhang Y, Wang L, Zheng X, Wang H, Wang G. Risk factors for macro vascular disease in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease. *Pak J Pharm Sci.* 2023;36(4) (Special):1297–1303.
166. Wu J, et al. Development and validation of a prediction model for all-cause mortality in maintenance dialysis patients: a multi-center retrospective cohort study. *Ren Fail.* 2024;46(1):2322039. <https://doi.org/10.1080/0886022X.2024.2322039>.
167. Li Y, Liu Y, Gao L, Tian C. Early impact of albuminuria on cardiac function in patients with chronic kidney disease: a prospective study. *Int J Cardiovasc Imaging.* 2024. <https://doi.org/10.1007/s10554-024-03056-4>.
168. Zhang Z, et al. A comparative study on the efficacy of fast-track surgery in the treatment of esophageal cancer patients combined

- with metabolic syndrome. *Oncol Lett.* 2017;14(4):4812–6. <https://doi.org/10.3892/ol.2017.6759>.
169. Shams S, Shafi S, Bodman-Smith K, Williams P, Mehta S, Ferns GA. Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: association with established cardiovascular risk factors. *Clin Chim Acta.* 2008;395(1–2):42–6. <https://doi.org/10.1016/j.cca.2008.04.026>.
 170. Zilae M, Kermany T, Tavalae S, Salehi M, Ghayour-Mobarhan M, Ferns GAA. Barberry treatment reduces serum anti-heat shock protein 27 and 60 antibody titres and high-sensitivity c-reactive protein in patients with metabolic syndrome: a double-blind, randomized placebo-controlled trial. *Phytother Res.* 2014;28(8):1211–5. <https://doi.org/10.1002/ptr.5117>.
 171. Gruden G, et al. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: a novel circulating marker for diabetic neuropathy. *Diabetes.* 2008;57(7):1966–70. <https://doi.org/10.2337/db08-0009>.
 172. Sookoian S, Castaño GO, Scian R, San Martino J, Pirola CJ. Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH). *Sci Rep.* 2016;6:22528. <https://doi.org/10.1038/srep22528>.
 173. Alfadda AA, et al. Proteomic analysis of mature adipocytes from obese patients in relation to aging. *Exp Gerontol.* 2013;48(11):1196–203. <https://doi.org/10.1016/j.exger.2013.07.008>.
 174. Zhang X, et al. PDIA3 knockdown exacerbates free fatty acid-induced hepatocyte steatosis and apoptosis. *PLoS One.* 2015;10(7):e0133882. <https://doi.org/10.1371/journal.pone.0133882>.
 175. Pizent A, Pavlovic M, Jurasovic J, Dodig S, Pasalic D, Mujagic R. Antioxidants, trace elements and metabolic syndrome in elderly subjects. *J Nutr Health Aging.* 2010;14(10):866–71. <https://doi.org/10.1007/s12603-010-0139-1>.
 176. Işık M, Tunç A, Beydemir Ş. Oxidative stress and changes of important metabolic gene expressions as a potential biomarker in the diagnosis of atherosclerosis in leukocytes. *Braz J Cardiovasc Surg.* 2022;37(4):481–7. <https://doi.org/10.21470/1678-9741-2020-0378>.
 177. Amor AJ, et al. Novel glycoproteins identify preclinical atherosclerosis among women with previous preeclampsia regardless of type 1 diabetes status. *Nutr Metab Cardiovasc Dis.* 2021;31(12):3407–14. <https://doi.org/10.1016/j.numecd.2021.08.041>.
 178. Kafeel S, Hashim Z, Fawwad A, Nawab SN. Predisposition of SOD1, GPX1, CAT genetic variants and their haplotypes in cataractogenesis of type 2 diabetes mellitus in Pakistan. *Acta Diabetol.* 2022;59(5):623–32. <https://doi.org/10.1007/s00592-021-01832-5>.
 179. Kosmalski M, Szymczak-Pajor I, Drzewoski J, Śliwińska A. Non-alcoholic fatty liver disease is associated with a decreased catalase (CAT) level, CT genotypes and the T allele of the -262 C/T CAT polymorphism. *Cells.* 2023. <https://doi.org/10.3390/cells12182228>.
 180. Copenhaver M, Yu C-Y, Hoffman RP. Complement components, C3 and C4, and the metabolic syndrome. *Curr Diabetes Rev.* 2019;15(1):44–8. <https://doi.org/10.2174/1573399814666180417122030>.
 181. Copenhaver MM, Yu C-Y, Zhou D, Hoffman RP. Relationships of complement components C3 and C4 and their genetics to cardiometabolic risk in healthy, non-Hispanic white adolescents. *Pediatr Res.* 2020;87(1):88–94. <https://doi.org/10.1038/s41390-019-0534-1>.
 182. Ursini F, Abenavoli L. The emerging role of complement C3 as a biomarker of insulin resistance and cardiometabolic diseases: preclinical and clinical evidence. *Rev Recent Clin Trials.* 2018;13(1):61–8. <https://doi.org/10.2174/1574887112666171128134552>.
 183. Chen C-H, Sun L, Mochly-Rosen D. Mitochondrial aldehyde dehydrogenase and cardiac diseases. *Cardiovasc Res.* 2010;88(1):51–7. <https://doi.org/10.1093/cvr/cvq192>.
 184. Rodríguez-Zavala JS, Calleja LF, Moreno-Sánchez R, Yoval-Sánchez B. Role of Aldehyde Dehydrogenases in Physiopathological Processes. *Chem Res Toxicol.* 2019;32(3):405–20. <https://doi.org/10.1021/acs.chemrestox.8b00256>.
 185. Tai J, et al. Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype. *Cancer Sci.* 2024;115(2):564–74. <https://doi.org/10.1111/cas.16042>.
 186. Ulloque-Badaracco JR, et al. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis. *Lipids Health Dis.* 2023;22(1):98. <https://doi.org/10.1186/s12944-023-01860-w>.
 187. Masuda R, et al. Plasma lipoprotein subclass variation in middle-aged and older adults: Sex-stratified distributions and associations with health status and cardiometabolic risk factors. *J Clin Lipidol.* 2023;17(5):677–87. <https://doi.org/10.1016/j.jacl.2023.06.004>.
 188. Korjian S, et al. Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction. *Eur Heart J Cardiovasc Pharmacother.* 2023;9(4):387–98. <https://doi.org/10.1093/ehjcvp/pvad014>.
 189. Bhale AS, Venkataraman K. Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics. *Biomed Pharmacother.* 2022;154:113634. <https://doi.org/10.1016/j.biopha.2022.113634>.
 190. Lallukka S, et al. Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans. *Thromb Haemost.* 2017;117(2):286–94. <https://doi.org/10.1160/TH16-09-0716>.
 191. Moin ASM, Sathyapalan T, Butler AE, Atkin SL. Coagulation factor dysregulation in polycystic ovary syndrome is an epiphenomenon of obesity. *Clin Endocrinol (Oxf).* 2023;98(6):796–802. <https://doi.org/10.1111/cen.14904>.
 192. Masood A, Benabdelkamel H, Ekhzaimy AA, Alfadda AA. Plasma-based proteomics profiling of patients with hyperthyroidism after antithyroid treatment. *Molecules.* 2020. <https://doi.org/10.3390/molecules25122831>.
 193. Vasseur C, Baudin-Creuzat V. Role of alpha-hemoglobin molecular chaperone in the hemoglobin formation and clinical expression of some hemoglobinopathies. *Transfus Clin Biol.* 2015;22(1):49–57. <https://doi.org/10.1016/j.tracli.2015.01.002>.
 194. Wu M, Zhang Y. Combining bioinformatics, network pharmacology and artificial intelligence to predict the mechanism of celastrol in the treatment of type 2 diabetes. *Front Endocrinol (Lausanne).* 2020;13:1030278. <https://doi.org/10.3389/fendo.2022.1030278>.
 195. Caira S, et al. Differential representation of liver proteins in obese human subjects suggests novel biomarkers and promising targets for drug development in obesity. *J Enzyme Inhib Med Chem.* 2017;32(1):672–82. <https://doi.org/10.1080/14756366.2017.1292262>.
 196. Cho H, et al. ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes. *Sci Rep.* 2017;7:44186. <https://doi.org/10.1038/srep44186>.
 197. An S, et al. Identification of key genes of diabetic cardiomyopathy in hiPSCs-CMs based on bioinformatics analysis. *Mol Cell Biochem.* 2024. <https://doi.org/10.1007/s11010-023-04915-9>.
 198. Park H-S, et al. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. *Autophagy.* 2021;17(9):2549–64. <https://doi.org/10.1080/15548627.2020.1834711>.

199. Maumus S, Marie B, Vincent-Viry M, Siest G, Visvikis-Siest S. Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. The role of FGB-455 G/A polymorphism. *Atherosclerosis*. 2007;191(2):369–76. <https://doi.org/10.1016/j.atherosclerosis.2006.04.003>.
200. Yamane T, et al. Serum DJ-1 level is positively associated with improvements in some aspects of metabolic syndrome in Japanese women through lifestyle intervention. *Nutr Res*. 2014;34(10):851–5. <https://doi.org/10.1016/j.nutres.2014.09.004>.
201. Collins AR, et al. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. *Circ Res*. 2009;104(6):e42–54. <https://doi.org/10.1161/CIRCRESAHA.108.188771>.
202. Inberg A, Linial M. Protection of pancreatic beta-cells from various stress conditions is mediated by DJ-1. *J Biol Chem*. 2010;285(33):25686–98. <https://doi.org/10.1074/jbc.M110.109751>.
203. Mourino-Alvarez L, et al. A comprehensive study of calcific aortic stenosis: from rabbit to human samples. *Dis Model Mech*. 2018. <https://doi.org/10.1242/dmm.033423>.
204. Savill SA, Leitch HF, Harvey JN, Thomas TH. Inflammatory adipokines decrease expression of two high molecular weight isoforms of tropomyosin similar to the change in type 2 diabetic patients. *PLoS One*. 2016;11(9):e0162908. <https://doi.org/10.1371/journal.pone.0162908>.
205. Brodehl A, et al. The novel α B-crystallin (CRYAB) mutation p. D109G causes restrictive cardiomyopathy. *Hum Mutat*. 2017;38(8):947–52. <https://doi.org/10.1002/humu.23248>.
206. Sun C, Sedimbi SK, Ashok AK, Sanjeevi CB. Swedish childhood diabetes and the diabetes incidence in Sweden study groups, CRYAB-650 C>G (rs2234702) affects susceptibility to Type 1 diabetes and IAA-positivity in Swedish population. *Hum Immunol*. 2012;73(7):759–66. <https://doi.org/10.1016/j.humimm.2012.04.004>.
207. Zheng Y, Lang Y, Qi Z, Gao W, Hu X, Li T. PIK3R1, SPNB2, and CRYAB as potential biomarkers for patients with diabetes and developing acute myocardial infarction. *Int J Endocrinol*. 2021;2021:2267736. <https://doi.org/10.1155/2021/2267736>.
208. Karahan F, Atay A, Dilek FH, Tavusbay C, Atahan MK. Acute mesenteric thrombosis in a pregnant woman with Factor V Leiden mutation with a history of in vitro fertilization and embryo transfer: case report and literature review. *Rev Colomb Obstet Ginecol*. 2022;73(4):388–95. <https://doi.org/10.18597/rcog.3854>.
209. Yang J, Mao H, Sun L. Congenital coagulation factor V deficiency with intracranial hemorrhage. *J Clin Lab Anal*. 2022;36(11):24705. <https://doi.org/10.1002/jcla.24705>.
210. Uitte de Willige S, Standeven KF, Philippou H, Ariëns RAS. The pleiotropic role of the fibrinogen gamma' chain in hemostasis. *Blood*. 2009;114(19):3994–4001. <https://doi.org/10.1182/blood-2009-05-217968>.
211. Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. *Ann N Y Acad Sci*. 2001;936:580–93. <https://doi.org/10.1111/j.1749-6632.2001.tb03546.x>.
212. Pan H-T, et al. Proteomics and bioinformatics analysis of cardiovascular related proteins in offspring exposed to gestational diabetes mellitus. *Front Cardiovasc Med*. 2022;9:1021112. <https://doi.org/10.3389/fcvm.2022.1021112>.
213. Massberg S, et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprotection and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. *Circulation*. 2005;112(8):1180–8. <https://doi.org/10.1161/CIRCULATIONAHA.105.539221>.
214. Forrester SJ, Kikuchi DS, Hernandez MS, Xu Q, Griendling KK. Reactive oxygen species in metabolic and inflammatory signaling. *Circ Res*. 2018;122(6):877–902. <https://doi.org/10.1161/CIRCRESAHA.117.311401>.
215. Zhao Y-X, Borjigin S, Yan Z-L. Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin. *World J Diabetes*. 2022;13(3):224–39. <https://doi.org/10.4239/wjdv13.i3.224>.
216. Blass JP, Sheu RK, Gibson GE. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. *Ann N Y Acad Sci*. 2000;903:204–21. <https://doi.org/10.1111/j.1749-6632.2000.tb06370.x>.
217. Fiorentino TV, et al. Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. *Metabolism*. 2021;114: 154416. <https://doi.org/10.1016/j.metabol.2020.154416>.
218. Liao M, et al. Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. *Endocrine*. 2024;83(1):227–41. <https://doi.org/10.1007/s12020-023-03487-4>.
219. Camargo A, et al. Endoplasmic reticulum stress in adipose tissue determines postprandial lipoprotein metabolism in metabolic syndrome patients. *Mol Nutr Food Res*. 2013;57(12):2166–76. <https://doi.org/10.1002/mnfr.201300036>.
220. Qiu YH, Xu YL, Zhang WH. Effect of GSTM1, GSTT1, and GSTP1 Ile105Val polymorphisms on susceptibility to gestational diabetes mellitus. *Genet Mol Res*. 2016. <https://doi.org/10.4238/gmr.15027711>.
221. Jamil H, et al. A study of association between presence or absence of GSTT1 and GSTM1 and/or single nucleotide polymorphism in FABP2 and GSTP1 with incidence of diabetes type 2: A case-control study. *J Pak Med Assoc*. 2022;72(4):714–20. <https://doi.org/10.47391/JPMA.1337>.
222. Kordi-Tamandani DM, Hashemi M, Birjandian E, Bahari A, Valizadeh J, Torkamanzehi A. Lack of association of GSTT1 and GSTP1 genes methylation and their expression profiles with risk of NAFLD in a sample of Iranian patients. *Clin Res Hepatol Gastroenterol*. 2011;35(5):387–92. <https://doi.org/10.1016/j.clinre.2011.01.015>.
223. Tavoulari S, Sichrovsky M, Kunji ERS. Fifty years of the mitochondrial pyruvate carrier: New insights into its structure, function, and inhibition. *Acta Physiol (Oxf)*. 2023;238(4):e14016. <https://doi.org/10.1111/apha.14016>.
224. Qvarnstrom M, et al. Association of salivary lysozyme and C-reactive protein with metabolic syndrome. *J Clin Periodontol*. 2010;37(9):805–11. <https://doi.org/10.1111/j.1600-051X.2010.01605.x>.
225. Ahmad Z, Laughlin TF. Medicinal chemistry of ATP synthase: a potential drug target of dietary polyphenols and amphibian antimicrobial peptides. *Curr Med Chem*. 2010;17(25):2822–36. <https://doi.org/10.2174/092986710791859270>.
226. MacDonald MJ, et al. Identification of ATP synthase as a lipid peroxide protein adduct in pancreatic islets from humans with and without type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2013;98(4):E727–31. <https://doi.org/10.1210/jc.2012-4203>.
227. Moon S-S, et al. Association of pyruvate dehydrogenase kinase 4 gene polymorphisms with type 2 diabetes and metabolic syndrome. *Diabetes Res Clin Pract*. 2012;95(2):230–6. <https://doi.org/10.1016/j.diabres.2011.09.035>.
228. Luo Y, Zhang L, Zhao T. Identification and analysis of cellular senescence-associated signatures in diabetic kidney disease by integrated bioinformatics analysis and machine learning. *Front Endocrinol (Lausanne)*. 2023;14:1193228. <https://doi.org/10.3389/fendo.2023.1193228>.
229. Zephy D, Ahmad J. Type 2 diabetes mellitus: role of melatonin and oxidative stress. *Diabetes Metab Syndr*. 2015;9(2):127–31. <https://doi.org/10.1016/j.dsx.2014.09.018>.
230. Doumatey AP, et al. Global gene expression profiling in omental adipose tissue of morbidly obese diabetic African Americans. *J*

- Endocrinol Metab. 2015;5(3):199–210. <https://doi.org/10.14740/jem286w>.
231. Fei J, Xiao C, Yang M, Zhou X, Gong P. Inhibition of SNCG suppresses the proliferation of lung cancer cells induced by high glucose. *Mol Med Rep*. 2021. <https://doi.org/10.3892/mmr.2020.11777>.
232. Sharma S, Bennet L, Laucyte-Cibulskiene A, Christensson A, Nilsson PM. Associations between birth weight and adult apolipoproteins: The LifeGene cohort. *PLoS One*. 2024;19(3):e0299725. <https://doi.org/10.1371/journal.pone.0299725>.
233. Björnson E, Adiels M, Bergström G, Gummesson A. The relationship between genetic liver fat and coronary heart disease is explained by apoB-containing lipoproteins. *Atherosclerosis*. 2024;388: 117397. <https://doi.org/10.1016/j.atherosclerosis.2023.117397>.
234. Tragomalou A, et al. Non-traditional cardiovascular risk factors in adolescents with obesity and metabolic syndrome may predict future cardiovascular disease. *Nutrients*. 2023. <https://doi.org/10.3390/nu15204342>.
235. Xu F, et al. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH. *Redox Biol*. 2020;36: 101634. <https://doi.org/10.1016/j.redox.2020.101634>.
236. Butcher JT, Johnson T, Beers J, Columbus L, Isakson BE. Hemoglobin α in the blood vessel wall. *Free Radic Biol Med*. 2014;73:136–42. <https://doi.org/10.1016/j.freeradbiomed.2014.04.019>.
237. Insenser M, Vilarrasa N, Vendrell J, Escobar-Morreale HF. Remission of diabetes following bariatric surgery: plasma proteomic profiles. *J Clin Med*. 2021. <https://doi.org/10.3390/jcm10173879>.
238. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. *Arterioscler Thromb Vasc Biol*. 2007;27(2):352–8. <https://doi.org/10.1161/01.ATV.0000254150.97741.fe>.
239. Bañuls C, et al. Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS. *Metabolism*. 2017;71:153–62. <https://doi.org/10.1016/j.metabol.2017.02.012>.
240. Sage AT, Holtby-Ottenhof S, Shi Y, Damjanovic S, Sharma AM, Werstuck GH. Metabolic syndrome and acute hyperglycemia are associated with endoplasmic reticulum stress in human mononuclear cells. *Obesity (Silver Spring)*. 2012;20(4):748–55. <https://doi.org/10.1038/oby.2011.144>.
241. Gawrieh S, et al. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. *Obes Surg*. 2010;20(12):1698–709. <https://doi.org/10.1007/s11695-010-0171-6>.
242. Rehati A, Abuduaini B, Liang Z, Chen D, He F. Identification of heat shock protein family A member 5 (HSPA5) targets involved in nonalcoholic fatty liver disease. *Genes Immun*. 2023;24(3):124–9. <https://doi.org/10.1038/s41435-023-00205-y>.
243. Ren Q, Sun Q, Fu J. Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease. *Autophagy*. 2024;20(2):221–41. <https://doi.org/10.1080/15548627.2023.2254191>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Alba Rodriguez-Muñoz^{1,2,3} · Hanieh Motahari-Rad⁴ · Laura Martin-Chaves^{5,6} · Javier Benitez-Porres^{2,7} · Jorge Rodriguez-Capitan^{5,8} · Andrés Gonzalez-Jimenez⁹ · Maria Insenser¹⁰ · Francisco J. Tinahones^{1,2,3,6} · Mora Murri^{1,2,3,4}

✉ Maria Insenser
insensermaria@gmail.com

✉ Mora Murri
moramurri@gmail.com

¹ Endocrinology and Nutrition UGC, Hospital Universitario Virgen de La Victoria, Málaga, Spain

² Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Hospital Clínico Virgen de La Victoria, Málaga, Spain

³ CIBER Fisiopatología de La Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Málaga, Spain

⁴ Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran

⁵ Heart Area, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain

⁶ Department of Dermatology and Medicine, Faculty of Medicine, University of Malaga, Malaga, Spain

⁷ Department of Human Physiology, Physical Education and Sport, Faculty of Medicine, University of Malaga, Malaga, Spain

⁸ Biomedical Research Network Center for Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain

⁹ ECAI Bioinformatic Institute of Biomedical Research of Malaga (IBIMA), Malaga, Spain

¹⁰ Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology & Nutrition, Hospital Universitario Ramón y Cajal & Universidad de Alcalá & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) & Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain